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Abstract 
Wastewater treatment plants (WWTPs) are a primary source of many contaminants to the 
environment. Processing complex mixtures of waste, they can result in the continuous 
discharge of bioactive and endogenous compounds into sensitive aquatic ecosystems. 
Isoprostanes (IsoPs) are a class of potential emerging contaminants, produced in a range of 
vertebrate species, including humans, in response to oxidative stress. Released following 
exposure to various toxicants or disease, IsoPs are also mediators of inflammatory processes. 
Even in the low nanomolar range, these compounds have potent biological activities and can 
induce multiple pathophysiological responses, stimulating the continuation of oxidative stress. 
Their urinary excretion provides a mechanism for the entry of IsoPs to WWTPs and 
subsequently the wider environment, where they may initiate a cycle of oxidative stress in 
aquatic biota exposed to these compounds. Following which, additional IsoPs may be produced 
within these organisms, further perpetuating this cycle of toxicity.   
 
To examine WWTPs as a source of IsoPs to the environment, an analytical method for their 
detection in wastewater based on solid phase extraction (SPE) and gas chromatography mass 
spectroscopy (GC-MS) was developed. Firstly, the novel method involved a deconjugation 
treatment with b-glucuronidase to increase the concentration of IsoPs available for detection. 
Subsequently, SPE followed by either silica gel chromatography or hexane liquid-liquid 
extraction were used to extract and purify the samples, removing the matrix inferences. Finally, 
a MSTFA derivatisation method was developed and resulted in the reliable detection of these 
compounds through GC-MS analysis.  
 
A survey of Canterbury WWTPs was then conducted to assess the concentrations of IsoPs 
present in both wastewater influent and effluent. These compounds were detected at three of 
the four WWTPs assessed, with recovery-corrected concentrations ranging from ND-79.9 ng/L 
and ND-55.9 ng/L in the influent and effluent, respectively. As IsoPs were detected in 
wastewater effluent, this indicates that these compounds are not sufficiently removed during 
the treatment process, and that WWTPs may represent a source of these compounds to the 
environment. Further research is required to improve the extraction and purification methods 
in order to reliably assess the concentrations of IsoPs in wastewater. A series of comprehensive 
environmental surveys and ecotoxicological assays are also necessary to determine the 
potential roles of IsoPs as emerging contaminants.    
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Chapter 1 
Introduction and research objectives 
1.1 Wastewater treatment plants, emerging contaminants and 
environmental pollution 
Wastewater treatment plants (WWTPs) are a primary source of many anthropogenic pollutants 
entering the environment.1-3 Wastewater overflow, the release of effluent and the application 
of sewage sludge as a soil amendment each contribute to their total discharge.4, 5 During 2018, 
there were forty wastewater overflow events in Christchurch, New Zealand. Each incident 
resulted in the discharge of untreated wastewater to the environment and heralded the potential 
for contamination to remain for up to two days once the source had stopped.6 On average, 
sewage overflows across the country related to wet weather increased by 379%, compared to 
the previous year.7 Growing populations, aging infrastructure, and an increase in severe 
weather events due to climate change are all factors which place a strain on our wastewater 
systems and infrastructure. Each factor compromises the transport of wastewater to the 
treatment plants, while also contributing to an overall decrease in plant function and treatment 
efficiency, potentially resulting in the purposeful or accidental discharge of untreated 
wastewater to the environment. These issues, combined with the release of properly treated 
wastewater effluent, accounts for a burgeoning issue worldwide. 
 
Complex mixtures of chemical contaminants from a combination of municipal, industrial and 
agricultural waste inputs are processed in WWTPs.1, 4, 5 Although WWTPs remove many 
contaminants from waste, inadequate treatment methods or the transformation of compounds 
can result in their incomplete removal, especially in developing countries.4, 8 9, 10 Of particular 
concern are emerging contaminants (ECs), which are defined as newly-synthesised compounds 
and those which have only recently been detected or identified as being contaminants of 
concern. In conjunction with advancing technology, population growth, and changing 
socioeconomic classes, the list of potential ECs is increasing.1,10 Compounds which previously 
have not been of concern, may now pose risks due to the sheer volume produced and 
discharged. Many of these compounds exert ecotoxicological impacts in their receiving 
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environments, especially on vulnerable aquatic species.9 In many countries, such as New 
Zealand, important species (e.g. native or food source) are already in decline11 and additional 
pressures from exposure to contaminants have the potential to push these ecosystems past their 
tipping points.1 
1.1.1 Synthetic emerging contaminants  
Synthetic ECs, including pharmaceuticals and personal care products (PPCPs), pesticides and 
microplastics are of increasing environmental concern.9, 12 Many of these compounds are 
designed specifically to ensure their long-term chemical stability or potent biological function. 
In some instances, even if a compound has not been developed for these purposes, it may still 
possess certain undesirable biological activities due to structural similarities to natural 
biological compounds.1 For example, various pesticides, industrial compounds, and PPCP 
preservatives possess endocrine disrupting properties as a result of their structural similarities 
to steroid hormones.1, 10 There is concern over the presence of these compounds in the 
environment as they do not exist in isolation, but as diverse mixtures, which could result in 
complex and adverse synergistic effects.4 Additionally, even if a parent compound is perceived 
as harmless, its metabolites may be more persistent, with similar or more harmful 
ecotoxicological impacts. Both parent and daughter compounds can have complicated and 
poorly-understood environmental characteristics and fates, making the regulation, 
management, or mitigation of these contaminants difficult.9, 13, 14 Even if one is removed from 
the market, another may easily take its place with an even less understood toxicity. Warranted 
concern over the threats that these poorly-understood compounds pose has resulted in increased 
research and the intensification of existing contaminant sampling programmes.12 
1.1.2 Endogenous emerging contaminants 
Biological pollutants make up another category of micropollutants likely to become of 
increased importance as ECs.12 These include pathogenic viruses and bacteria, and endogenous 
compounds. The latter may be defined as those which originate from within an organism or 
cell.15 Endogenous compounds may be produced in response to natural or abnormal biological 
processes, and they often have additional roles in mediating biochemical processes.15, 16 
Changes in physiological state are associated with fluctuations in their concentration and rate 
of production, and while these changes can be linked to regular functions and metabolism, they 
can also be the result of exposure to external toxicants or disease.17 The synthesis of 
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endogenous compounds can result in the propagation of pathological responses due to their 
biological roles, especially if they are produced as a result of an abnormal or aggravated 
biological state. Bioactive endogenous compounds which are excreted by humans are of 
particular concern as potential ECs.1, 18 Steroid hormones and endocrine disrupting chemicals, 
such as estrogenic compounds and glucocorticoids, are examples of ECs which have been 
detected throughout environmental matrices. These compounds are capable of eliciting adverse 
effects at low but environmentally relevant concentrations and their impacts have been widely 
assessed.1, 19, 20 WWTPs contribute significantly to the discharge of steroid hormones, as most 
plants are not completely equipped to remove these contaminants excreted by humans. As a 
result, aquatic species living downstream of these sources are often the most exposed and 
severely affected by the contaminants contained in the effluent.21  
Our understanding of the biological activities of many endogenous compounds continues to 
develop. Despite this knowledge and our understanding of the conservation of metabolic 
processes between species,22 limited research has been conducted to investigate other non-
hormone compounds in terms of their potential roles as ECs. It is likely that humans or other 
mammal species are excreting compounds capable of eliciting pathological responses into 
WWTPs. These may then be discharged to the wider environment, where they could cause 
further harm to organisms in the receiving ecosystems. Many bioactive compounds have the 
potential to act as contaminants and impact species within an ecosystem if released at high 
enough concentrations.2  Further research into different potential contaminants is required, to 
enable the quantification and mitigation of the harm caused by these unknowns. Although only 
low levels may be excreted or released into wastewater, the consequences of exposure to 
endocrine disrupting compounds have demonstrated that species can still be severely impacted, 
leading to increasing concern over the potential harm that these relatively unstudied 
contaminants may be causing in the environment. 
1.1.3 Factors which may contribute to the concentrations of endogenous 
compounds in wastewater 
Although WWTPs are responsible for the removal of many contaminants from wastewater, 
inadequate treatment methods or the transformation of chemicals can result in their incomplete 
removal.4, 8 Increasing population density, substance abuse, and the continuous discharge of 
effluent may exacerbate the impacts of environmentally concerning concentrations of 
contaminants released into sensitive environments. Research is still required to determine 
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effective mechanisms to isolate, detect and manage these compounds.8, 23 Once released into 
the environment, despite rapid degradation rates, the continuous input of these compounds 
from WWTPs can result in pseudo-persistence and a long-term environmental presence.9 The 
concentrations of endogenous compounds discharged from a particular WWTP will vary based 
on the size of the population being served, the industries it is serving, and the population’s 
overall health.17 For many endogenous compounds, their production and excretion are 
dependent on organism health. It is expected that in lower socioeconomic areas where medical 
treatment may be limited, or areas where substance abuse is more prevalent, higher 
concentrations may be present in wastewater.17  
1.2 Wastewater epidemiology biomarkers as potential emerging 
contaminants 
1.2.1 Endogenous compounds as sewage biomarkers to assess community 
health  
The production and excretion of various endogenous compounds within an organism are 
largely dependent on its health status.24 Therefore, analysis of faeces or urine for a specific 
compound or biomolecule can provide a non-invasive method to assess health, based on an 
understanding of how biological state dictates its production. This concept is being exploited 
for wastewater epidemiology, where the measurement of endogenous or exogenous 
compounds excreted by humans can be used as a tool to assess community health.16, 17, 25 
Originally proposed to evaluate substance abuse, wastewater epidemiology has been extended 
further, through to understanding community exposure to various ECs and assessing general 
health or disease status.17, 25, 26 The latter is performed either directly, by searching for 
endogenous inflammatory biomarkers (produced in response to disease or inflammatory 
processes), or indirectly, through analysing for pharmaceutical drugs which provides an idea 
of their consumption and the proportion of the population that require them.25 
 
Many different endogenous compounds have been proposed as potential health biomarkers 
because of their relationship or production in response to common diseases (such as 
atherosclerosis, diabetes, and cancer), general ill-health, and physiological dysfunction or 
stress.25 Understanding the physiological factors which result in the production of a biomarker, 
as well as individual rates of excretion, are important for its success. Then, through analysing 
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the concentration of a “successful biomarker” in influent, an understanding of the overall health 
of a population can be determined.25 A subset of the currently proposed sewage biomarkers 
also have known or suspected roles in the pathogenesis of health issues in humans.17 Whereby, 
elevated concentrations of pro-inflammatory molecules have been linked to the exacerbation 
of various diseased states, including inflammation, cell proliferation, cell death, and many other 
biological processes. Table 1-1 provides a brief summary of proposed epidemiology markers 
which have additional known or suspected biological roles. Although only isoprostanes (IsoPs) 
have begun to be investigated for these roles, some of these other molecules, alongside IsoPs, 
may represent potential contaminants, justified by their urinary excretion and biological 
activities (Section 1.2.3).  
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Biomarkers Biomarker description Relationship to disease Urinary excretion Limitation  
CRP 
- An acute-phase protein involved 
in inflammation.  
- It may be used as a biomarker of 
oxidative stress in humans.27 
- Can be detected in plasma in response to cancers, 
cardiovascular disease (CVD), urinary tract 
infections, pneumonia, appendicitis and 
meningitis.27-29 
- Elevated levels are linked to the potential 
pathogenesis of disease.30   
- Yes.  
- It can be detected at 
elevated levels in 
urine in response to 
disease. 
- More information relating 
to its urinary excretion 
and relationship to the 





- They are metabolites of tyrosine, 
produced by the action of 
myeloperoxidase (MPO), an 
oxidising enzyme involved in 
inflammation.31,32  
- 3-chlorotyrosine and nitrotyrosine 
serve as clinical biomarkers of 
MPO activity.31, 32  
- 3-chlorotyrosine causes endothelial dysfunction, 
increases free-radical production, and is linked to 
atherosclerosis.33  
- High levels are found in patients with coronary 
artery heart disease and asthma. 
- Nitrotyrosine levels are elevated in diabetes and 
influenza patients and smokers.33  
- Protein nitrotyrosine formation may be a risk 
factor for CVD.34 
- Believed to have a role in atherosclerosis.34  
- Yes.  
- Elevated levels can 
be detected in urine 
in relation to multiple 
pathological 
conditions in both 
humans and other 
animals. 
- Halogenated compounds 
may be released from food 
and other sources into 
sewage.17 
- Nothing is known about 
their fate or concentrations 
in sewage.  
- It is not known if exposure 
results in the propagation 





- o,o’-Dityrosine forms when a 
radical (e.g. hydroxyl) crosslinks 
tyrosine residues.35  
- Increased plasma concentrations are detected as a 
result of oxidative stress in children.31 
- Increased concentrations are linked to 
atherosclerosis and aging.36  
- Yes. 
-  Elevated levels can 
be detected in urine 
in response to 
disease. 
- Very little is known about 
its fate in urine. 
- Nothing is known of its 
fate in sewage. 
Isoprostanes 
- A group of compounds which are 
produced in response to the 
peroxidation and cyclisation of 
fatty acids.  
- They are used as clinical 
biomarkers of oxidative stress.  
- They are formed in response to, and have roles in 
a range of acute and chronic inflammatory 
diseases.  
- Patients suffering from diseases such as 
hypertension, diabetes, obesity, 
neurodegenerative disease and asthma have 
elevated urinary and plasma levels.  
- Yes.  
- They can be detected 
at elevated levels in 
urine in response to 
disease. 
- Limited information on 
their behaviour in sewage 
is known.  
Table 1-1. Proposed wastewater epidemiology biomarkers and limitations to their understanding as emerging contaminants. 
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1.2.2 Wastewater epidemiology and emerging contaminant interface 
In a wastewater epidemiology context, the bioactivity of a compound is not of primary 
importance. However, wastewater epidemiology does intersect with EC research.16 From an 
EC perspective, any compounds released into wastewater at high enough concentrations, with 
additional biological roles, may represent potential contaminants. A holistic approach can be 
applied to the two fields, as certain characteristics of potential wastewater biomarkers match 
the characteristics of potential contaminants, including: (I) Excretion in the urine or faeces in 
constant or consistent concentrations; (II) Present in wastewater at detectable concentrations; 
and III) Chemically stable in wastewater.17, 24, 37 Although these compounds may not have 
negative biological effects in the originating species or organism, other species may react 
adversely in response to exposure. Moreover, estrogens make a pertinent example. Natural 
forms of these hormones are important for biological and physiological function throughout 
organisms.38 Females of child-bearing age naturally have greater concentrations of estrogenic 
compounds compared to individuals in different life-stages (e.g. children or post-menopausal 
women), sexes, or species. These same elevated concentrations are not necessary for biological 
functions in latter groups of individuals, and exposure to additional xenoestrogens has the 
potential to induce adverse effects.39 These include reduced sperm counts, premature puberty, 
lower fertility rates, and other forms of altered physiology.1 So although females may be 
exposed to high concentrations of estrogens through their natural production and from birth 
control pills, what they excrete into sewage can have a continued and unwanted secondary 
impact on other individuals or species. 
 
Population growth will likely increase the concentration of endogenous compounds present in 
wastewater,16 both improving their detection in epidemiology studies and increasing the risk 
they pose to the environment. As previously mentioned, more research investigating other 
endogenous compounds as potential ECs is required.40 Epidemiological research on potential 
biomarkers has provided a useful resource and perspective on many different compounds 
(Section 1.2.1), which may otherwise not have been considered as potential contaminants. 
Whether or not they prove detrimental to the environment, or are excreted at great enough 
concentrations to pose a threat, wastewater epidemiology provides a platform upon which 
further investigations can be conducted.  
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1.3 Isoprostanes: Clinical and epidemiological biomarkers of oxidative 
stress 
1.3.1 An introduction to isoprostanes 
Isoprostanes are a group of bioactive, clinical biomarkers produced in response to oxidative 
stress in many vertebrate species, including humans.41-43 These prostaglandin-like compounds 
are formed in vivo through the free radical-catalysed peroxidation of membrane-bound, 
esterified fatty acids (Section 1.3.2).44, 45 In the blood of healthy individuals, IsoPs are found 
at nanomolar concentrations which can then increase by several orders of magnitude following 
an oxidative stress event or when the body is in a diseased state (e.g. vascular or pulmonary 
disease).41, 46, 47 IsoPs are formed throughout the body and as a result they have been detected 
in a range of biological matrices, including amniotic fluid,48 cerebrospinal fluid,49 
atherosclerotic plaques,50 exhaled breath condensate,51 plasma,52 and urine.53 Coupled with 
their abundant formation in response to oxidative stress and oxidative stress-linked diseases, 
this has led to the use of IsoPs as clinical biomarkers of these compromised physiological states 
(Section 1.3.4). The elevated concentrations of these compounds in plasma and urine provides 
an advantageous method to determine oxidative stress status and disease progression in many 
species. Additionally, their presence in urine has resulted in their use as wastewater 
epidemiology biomarkers (1.4.2). Which furthermore, has led to the consideration of their 
potential role as ECs, as proposed in the work of Gaw and Glover (2016)18 and subsequently, 
Pais et al. (2018).54 The theory behind the roles of IsoPs as ECs capable of participating in 
feedback loops of toxicity is further explained below (Section 1.5).  
1.3.2 Biosynthesis of isoprostanes   
The biosynthetic pathways of IsoPs proceed through several radical steps and provide a 
mechanism for the formation of multiple classes of IsoPs, which differ based on the functional 
groups on the prostane ring.55, 56 While the following pathway (Figure 1-1) describes the 
formation of F2-IsoPs, D2/E2 IsoPs can also be produced through rearrangement of the 
endoperoxide intermediates. The D2/E2 IsoPs are formed in competition to the F2 series, 
especially when under depletion of reducing agents (e.g. a-tocopherol and ascorbic acid).55 
 
Following an oxidative stress injury which results in the release of free radicals in the cellular 
membranes, the generation of F2-IsoPs is initiated by the abstraction of a bis-allylic hydrogen  
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Figure 1-1. Mechanism of formation for the 15 series F2-IsoPs from the free radical- initiated 
peroxidation of arachidonic acid. 
 Introduction  
 10 
atom from arachidonic acid by a radical species.55 Subsequently, the radical reacts with a 
molecule of oxygen (O2), resulting in the formation of a peroxyl radical which then undergoes 
5-exo cyclisation before it reacts with a second oxygen molecule. A final reductive sequence 
of the endoperoxide and hydroperoxide functionalities leads to the formation of four 
regioisomeric F2-IsoPs, dependent on the site of hydrogen abstraction and oxygen insertion. 
For each of the four regioisomers, there are 8 racemic diastereoisomers. Although there may 
be 64 possible compounds generated, some predominate over others, such as the 5 and 15 F2-
IsoP series which are formed in greater proportions compared to the 8- and 12-series as they 
do not undergo further oxidation.55, 56, 57 
 
Isoprostane formation predominantly occurs in esterified form. Most of the precursor fatty 
acids are membrane bound, and exist as phospholipid esters in the interior of cell membranes.44 
Phospholipase action releases the IsoP molecules, whereby they circulate in the plasma and 
can be excreted in the urine in free form or as glucuronic acid conjugates (Figure 1-2). Once in 
circulation, these compounds can also undergo metabolism to form additional metabolites. 15-
F2t-IsoP, for example, is b-oxidised to form the intermediate compound 2,3-dinor-15-F2t-IsoP, 
which further reduces to 2,3-dinor-5,6-dihydro-15-F2t-IsoP.58, 59 
 
Figure 1-2. Glucuronidation reaction of 15-F2t-IsoP, one of the more commonly assessed IsoP 
isomers. 
1.3.3 Physiological roles and consequences of free radicals and reactive 
oxygen species  
Free radicals are defined as highly reactive chemical species which contain one or more 
unpaired electrons in their outer orbitals.55 In comparison, reactive oxygen species (ROS) are 
also chemically reactive compounds, however these are specifically oxygen-containing 
molecules. These include oxygen-centred radicals, oxygen ions and peroxides. Hydrogen 
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peroxide (H2O2), superoxide anion (O2˙-), hydroxyl radicals (˙OH), alkoxyl radicals (RO˙) and 
peroxyl radicals (ROO˙) are the most common ROS generated in living organisms. Other 
reactive species include nitric oxide (NO), peroxynitrite (ONOO-), hypochlorous acid (HOCl) 
and other carbon-centred radicals.55 ROS produced in vivo are derived from both endogenous 
processes (e.g. primarily metabolic and respiratory processes) and exposure to exogenous 
toxins (e.g. environmental pollutants, radiation injury, lifestyle toxins, etc).60 Redox reactions 
occurring during aerobic metabolism also result in the continuous generation of ROS.61 
Mitochondria in particular, are a major source of these endogenous ROS in cells. While 
producing energy, the electron transport chain releases small amounts of superoxide due to the 
‘leaking’ of electrons directly to oxygen.62 An estimated 1-4% of oxygen reacting with the 
electron transport train is incompletely reduced to the superoxide anion by these ‘leaking’ 
electrons. Under conditions of cellular stress and ATP depletion an excess of superoxide and 
H2O2 causes the release of free iron (FeII) from iron-containing molecules, such as iron-sulfur 
proteins within the mitochondrial membrane. This promotes the formation of the highly 
reactive hydroxyl radical, which can cause further damage.55 
 
ROS production also plays an important role in immune defence. Phagocytes are activated in 
response to inflammatory mediators and foreign micro-organisms. Then, nicotine adenine 
dinucleotide phosphate oxidase (NADPH NOX) produces superoxide anions catalysing the 
transfer of electrons from NADPH to molecular oxygen to form superoxide.63 Additionally, 
myeloperoxidase, a heme-containing phagocytic enzyme, produces hypochlorous acid (HOCl) 
in neutrophils, through reactions with hydrogen peroxide and chloride at sites of inflammation. 
64 However, the production of ROS at these sites of inflammation can also cause further injury 
to surrounding tissues, compounding the state of oxidative stress.   
 
Often abnormal increases in oxidative stress within organisms, via endogenous processes or  
pro-oxidant exposure, is mitigated by antioxidant response. The balance between pro-oxidants 
and anti-oxidants is critical in maintaining the proper redox environment within cells for their 
health and survival.65 It can easily be disturbed by an overproduction of ROS or insufficient 
antioxidant defence mechanisms, resulting in oxidative stress.66 Under these conditions, high 
levels of ROS react non-specifically and rapidly with cellular biomolecules, resulting in DNA 
mutations, protein oxidation and lipid peroxidation.62 The oxidation of proteins impacts their 
activity and function. The overproduction of lipid peroxidation products has been linked to the 
pathogenesis of several diseases. Cellular activity and function is disrupted via oxidative 
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damage to cell membranes and the disturbance of membrane organisation, integrity, fluidity 
and permeability. In general, oxidative stress is increasingly being implicated in the aetiology 
of many human diseases.67, 68 These include autoimmune disorders, cancer, CVD, diabetes and 
neurodegenerative diseases.69 Therefore, many biomolecules with the ability or function to 
increase oxidative stress have also been implicated with the pathogenesis or progression of 
many diseases (e.g. aging, atherosclerosis, and neurodegenerative disease).61 Consequently, 
IsoP production is also linked to many of these diseases and processes (Section 1.3.4).  
1.3.4 Isoprostanes as biomarkers and mediators of oxidative stress  
Biomarkers  
The relationship between oxidative stress and (I) the production of IsoPs; and (II) the onset of 
disease; makes these compounds useful biomarkers. As mentioned previously (Section 1.3.3), 
oxidative stress is the result of an imbalance in biological redox status. A variety of stressors 
can disrupt this balance, driving it in favour of oxidants.55 The prevalence of physiological 
oxidative stress can disrupt redox signalling and damage biomolecules which can lead to the 
onset of disease, linking oxidative stress to a variety of chronic and noncommunicable diseases. 
IsoPs are used as clinical biomarkers of oxidative stress in humans.43 Many isomers, including 
15-F2t-Isop, the F2, D2, and E2 series, can be reliably detected in biological fluids (e.g. plasma 
and urine) at elevated concentrations in response to various stressors.43, 58, 70 Disease, lifestyle 
toxicants, and natural biological processes can all result in an increase in total IsoP production 
due to an increase in ROS and oxidative stress. Additional factors, such as exercise and diet 
may also contribute to their physiological concentrations and production.  
 
Generally, the concentrations of free 15-F2t-IsoP is greater in the urine (100-1200 ng/L) 
compared to plasma (0.035-45.1 ng/L).71 Coupled to the non-invasive nature of sample 
collection, urine provides a useful method to assess oxidative stress, disease status, and each 
of their relationships to exposure to environmental toxicants. Many diseases have shown 
associations with elevated levels of 15-F2t-IsoP. Of these, some of the more notable include: 
Alzheimer’s, congestive heart failure, cystic fibrosis, cancer (such as breast, prostate, and 
stomach), alcoholic liver disease, chronic renal insufficiency, obesity and diabetes, among 
others.72 However, a meta-analysis by van Erve et al. (2017)71 identified that the association 
between IsoP concentrations and disease-type differs from previously predicted values, with 
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Alzheimer’s, cancer, and obesity showing lower associations compared to many others despite 
their significant links to oxidative stress.71   
Mediators of biological processes and pathways  
IsoPs are not simply diagnostic by-products of oxidative stress. They have complex biological 
activities, whereby they can mediate many different inflammatory processes.45, 73, 74, 75 Of the 
cocktail of IsoP isomers produced, many are involved (both directly and indirectly) in natural 
and pathophysiology.76 These compounds initiate biological pathways through interactions 
with various biomolecules. Although, the entirety of biomolecules which they can interact with 
has yet to be fully determined. Based on research so far, it is theorised that IsoPs contribute to 
the functional and pathophysiological consequences of oxidative stress primarily through the 
interaction and the activation of the thromboxane A2 (TXA2) prostanoid receptor.45 Additional 
activities may also be mediated through interactions with a receptor unique to IsoPs45 or 
through other prostanoid receptors. The latter is unsurprising due to their structural similarities 
of IsoPs to prostanoid molecules.   
 
Thromboxane A2 is a highly reactive and short-lived molecule involved in many processes 
through interactions with the prostanoid receptor. These processes include angiogenesis, 
atherogenesis, hypertension, myocardial infarction, vasospasm, and thrombosis.77, 78 Because 
many IsoP isomers are able to interact with this receptor, elevated concentrations of IsoPs have 
been linked to many of these processes as well. Studies have found that the administration of 
IsoPs (e.g. 15-F2t-IsoP and 8-Iso-prostaglandin E2) can result in the significant increase of 
blood pressure in rats.79 However, these hypertensive effects are not observed in prostanoid 
receptor-deficient organisms and can also be prevented following the administration of 
prostanoid receptor antagonists.79, 80 Alongside these vasomotor effects, IsoPs have 
proatherogenic properties, contributing to the initiation, progression, and physiological 
complications of CVD.75, 81 Usually, TXA2 and prostanoid receptors play important roles in 
CVD progression, with roles regulating platelet activity, endothelial integrity, and leukocyte-
endothelial cell interaction.82 Based on the evidence, prostanoid receptor agonists other than 
TXA2,  such as IsoPs, may be important in regulating the initiation and progression of 
atherosclerosis. Especially given what has already been deduced surrounding IsoP-prostanoid 
receptor interactions.  
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Alongside these vasomotor effects, IsoPs can also lead to DNA synthesis and endothelial cell 
proliferation.83, 84 The role these effects have on the aetiology of pathophysiological conditions 
and disease processes has yet to be fully established. Although, it is theorised that these effects 
will also allow IsoPs to contribute to CVD and other diseases through inducing enhanced 
interactions between endothelial and immune cells, such as the monocytes and neutrophils.85 
In this case, likely through modulating endothelial cell-immune cell interactions through both 
prostanoid receptor dependent and independent mechanisms.86  
 
Studies have found that another mechanism through which IsoPs may be indirectly altering 
physiological state is by inducing prostaglandin formation. Basu (2006)87 suggests that 
exposure to pharmacologically-administered or endogenously-produced 15-F2t-IsoP, during an 
oxidative stress event, induces prostaglandin formation. Most probably, this occurs through the 
classic cyclooxygenase-catalysed arachidonic acid oxide ion reaction. This may have an 
important biological role in the pathogenesis of free radical-related diseases and the initiation 
of inflammation, as prostaglandins themselves have important roles in controlling various 
signalling pathways.87 These include balancing physiological (renal, vascular, parturition, 
labour induction) and pathological (vasoconstriction in diseased states and inflammation) 
status. If IsoPs are capable of directly impacting the availability of prostaglandins in the 
biological system, this may cause additional physiological (and pathophysiological) 
consequences, based on how different prostaglandin concentrations usually modulate these 
processes. These impacts may include contributions to acute inflammatory response or the 
progression of chronic inflammation.60 Therefore, in a situation where there is a sudden 
increase in IsoP concentrations, irrespective of the stimuli (e.g. acute or chronic oxidative 
stress, or exogenous administration of these compounds to the body), these physiological 
consequences may still be brought about, resulting in a cycle of oxidative stress due the 
initiation of F2-IsoP biosynthesis. This highlights an additional link between elevated IsoP 
concentrations and their subsequent roles in free radical-related disease, the initiation of 
inflammatory response and oxidative stress.60, 75 
 
Isoprostanes induce a diverse range of biological activities in the low nanomolar range, with 
many cell types being found to respond in a pathologically-relevant manner, following 
exposure to the molecules (Figure 1-3)74, 84, 88, 89 These effects have primarily been researched 
and documented in rodents and humans. However, due to the production of IsoPs throughout 
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mammalian and vertebrate species and the conservation of metabolic processes, similar 
mechanisms of action would be expected throughout species and cells. The biological effects 
are induced throughout IsoP classes, isomers and some metabolites, such as 2,3-dinor-5,6-
dihydro-15-F2t-IsoP. Involved in a variety of pathological conditions, even if they are not direct 
causal agents of disease, IsoPs are still agents capable of exacerbating such clinical 
conditions.90 Additionally, this mounting evidence suggests that they can cause the 
continuation of a cycle of oxidative stress following the initial event. IsoPs are also thought to 
be capable of acting synergistically, which can result in a response which is greater than the 
sum of individual IsoP effects,91 an effect analogous to the well-documented synergistic 
activity of xenoestrogens.92, 93 This is significant as many of the isomers have different 
biological potencies or activities. Therefore, based on the cocktail of compounds and 
biomolecules present and the cell type, a complex range of responses may be elicited by the 
IsoPs.90 Which raises the question, that should exogenous exposure to a cocktail of such 
compounds occur, would this result in the propagation of disease processes and further IsoP 
production?  
 
Figure 1-3. A scheme of various isoprostane-initiated physiological pathways, and their subsequent 























of disease  
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1.4 Methods for the quantification of isoprostanes in biological 
samples and wastewater for their roles as epidemiology biomarkers 
1.4.1 Methods of detection  
The methods currently available for IsoP quantification are primarily based on chromatogram 
separation with mass spectrometry detection (e.g. GC-MS and LC-MS) or immunological 
methods.91 Due to their relatively high chemical stability, chromatographic and mass 
spectrometric characteristics, GC-MS in negative chemical ionisation (NCI) mode has been 
shown to be a reliable analytical technique to assess these compounds.94 Following extraction, 
F2-IsoPs are most commonly derivatised to form pentafluoryl esters and trimethylsilyl ether 
(PFB-TMS) derivatives. Through this method, the pentafluorobenzyl (PFB) group esterifies to 
the carboxyl group of the IsoP, while the TMS groups derivatise the remaining hydroxyls, 
which allows the detection of a single, intense ion m/z 569.58, 70, 94, 95 To further improve this 
method, some researchers have developed tandem mass spectrometric methods. One of the 
biggest limitations to the use of PFB-TMS is the inability to distinguish between different F2-
IsoP compounds.  
 
High performance liquid chromatography mass spectrometry (HPLC-MS), with electrospray 
ionisation, is another selective and sensitive method considered comparable to GC-MS, with 
the advantage that sample preparation is simplified without the need for derivatisation.96 
Additionally, this method can enable differentiation between the F2-IsoP regioisomers, as 
unique ions can be identified in the lower m/z region dependent on the compound (e.g. 5-F2-
IsoP m/z 115, 15-F2-IsoP m/z 193, 8-F2-IsoP m/z 127, 12-F2-IsoP m/z 151).97 The development 
of these methods allowed 5-F2-IsoP and 5-epi-5-F2-IsoP to be determined as the most abundant 
IsoPs in human urine, despite 15-F2t-IsoP being the compound which is most commonly 
investigated and analysed in literature.96, 98 
 
Finally, while these mass spectrometry methods are useful due to their sensitivity and accuracy, 
they are not always accessible for all researchers and can be time consuming to conduct.96 To 
overcome these issues, commercially available radioimmunoassays (RIA) and enzyme 
immunoassays (EIA) have been designed.96 An example is the ELISA (enzyme-linked 
immunosorbent assay) kit. Although they are more accessible to researchers, they are readily 
compromised by the presence of interfering substances found in more complex biological 
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matrices or fluids. Extensive purification methods such as HPLC or thin layer chromatography 
(TLC) used alongside these kits can help under such circumstances, however if only partial 
purification occurs, the interfering substances can end up being concentrated down.96 
Additionally, the concentrations detected from EIA methods compared to others are not always 
comparable with mass spectrometric methods. This can be due to the EIA methods not always 
being specific to individual isomers, which can skew the results if there are multiple present 
within a sample. EIA methods can also be extremely biased, and this cross-reactivity can 
overestimate the concentrations of IsoPs present in a sample, even when there is a correlation 
between their results and those found through mass spectrometric methods.99 As such, clinical 
results achieved using spectrometry versus EIA should not be compared.76,96 
 
Extraction and purification procedures are necessary to optimise detection when handling 
biological samples, despite them being time-consuming and often leading to a loss of analyte. 
Solid phase extraction (SPE) occasionally followed by additional TLC purification is one of 
the most common IsoP isolation techniques. A multitude of SPE methods and cartridges have 
been trialled with IsoPs.70, 96 The more common cartridges include Oasis HLB,100 Oasis MAX, 
Strata X,101 Strata X-AW100 and reverse phase (C18),100, 102 some of which achieve recoveries 
ranging from 50-100% with relatively good reproducibility.100, 103 Of the extraction techniques 
there is little consistency in the properties of the molecules which are being targeted, as base-, 
neutral- and acidic- selective cartridges have all been used to varying degrees of success. 
Immunoaffinity chromatography (IAC) has also been used for IsoP extraction.42, 104 This 
technique effectively extracts the IsoPs without the need for the SPE or TLC steps, following 
which the sample can then be prepared for analysis. This reduction in steps is often useful as it 
reduces sample handling which can otherwise introduce the potential for loss in analyte or 
contamination.104 Commercially available columns have made this method more accessible to 
laboratories, but they are still relatively expensive.  
 
Deconjugation is an additional stage that can provide improved detection of IsoPs in urine 
samples.105 Glucuronide conjugates are formed through the enzyme-catalysed glucuronidation 
of compounds that contain either phenol, hydroxyl or carboxyl groups, yielding a more water-
soluble derivative for excretion from the body. As noted (Section 1.3.2, Figure 1-2), IsoPs are 
excreted from the body as these conjugates. It has been demonstrated through treatment of 
urine with b-glucuronidase, that a 40% increase in the concentrations of F2-IsoPs detected can 
be achieved.105 Additionally, given that some of these compounds are biologically active, the 
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formation of these IsoP-glucuronides may be important in moderating their biological 
activities.  
1.4.2 Isoprostanes as wastewater epidemiology markers  
As mentioned previously, various exogenous and endogenous compounds produced by humans 
have been proposed as potential wastewater epidemiology biomarkers (Section 1.2). Two 
groups (Ryu et al.106 and Santos et al.107, 108) have recently conducted pilot studies investigating 
the roles of IsoPs as wastewater-derived biomarkers of community health. In the first studies 
by Santos et al. (2015 and 2016),107, 108 the group used a commercially available ELISA kit 
(Detroit R&D, Inc) to quantify the concentrations of IsoPs in influent (1-16 ng/L)107, 108 and 
effluent (not detected).108 The samples were collected from three collection points from May 
to June 2014107 and over a one year period from May 2014 to June 2015.108 While the trends 
in concentrations were found to be consistent over time, they did vary between sites. The two 
collection sites which served larger and more urbanised populations had greater IsoP 
concentrations compared to the smaller site, meaning that IsoP concentrations are likely to be 
population-dependent. The group concluded that the molecules would make useful biomarkers 
in sewage to assess human behaviour and health.  
 
Although Santos et al. (2016)108 were unable to detect IsoPs in wastewater effluent, it is 
theorised that through including a deconjugation step, as used in the methods of Ryu et al. 
(2015 and 2016),106,109 improved detection may be achieved (Table 1-2). Ryu et al. (2015),106 
developed a method to detect 15-F2t-IsoP in wastewater using immunoaffinity extraction with 
LC-HRMS. β-glucuronidase was included as a pre-treatment which significantly increased the 
concentrations of IsoPs available for detection in wastewater influent samples (1-20 ng/L) 
(Figure 1-4). Ryu et al. (2015),106 also conducted a comprehensive study determining the 
correlation between oxidative stress and tobacco consumption based on composite influent 
samples collected from eleven cities within Europe.109 Their results showed a good correlation 
between tobacco consumption and IsoP concentrations detected, which similarly to Santos et 
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Table 1-2. Concentrations of isoprostanes which have been detected in wastewater in epidemiology 
pilot studies. 
Method  Lower detection limit Influent (ng/L) Effluent (ng/L) 
ELISA107, 108 0.005 ng/mL 1.0-16  ND 
IAC-LC-HRMS106, 109 
MQL 0.3 ng/mL 
IQL 0.1 ng/mL 
18.9-23.3  N/A 
MQL = Method quantification limit; IQL = Instrument quantification limit; ND = Not detected; 
N/A = Not applicable  
 
Figure 1-4. The effect of enzymatic deconjugation on 15-F2t-IsoP concentrations in sewage. Sourced 
from Ryu et al. (2015).106 
 
1.5 Isoprostanes as potential emerging contaminants  
Emerging contaminants and wastewater epidemiology biomarkers share many of the same 
characteristics (Section 1.2.2). Although research has begun assessing the concentrations of 
IsoPs for their use as epidemiology markers,106, 107, 108 wastewater analysis of IsoPs has not 
been conducted with consideration to their potential roles as ECs capable of inducing negative 
biological effects.18,54 WWTPs represent a portal for the entry of many contaminants to the 
environment. Based on their biological activity, chemical stability, and presence in wastewater, 
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It has already been noted that IsoPs have potent biological activities, and are involved in 
multiple pathways which have both positive and negative physiological consequences (Section 
1.3.4). From a clinical perspective, it has been theorised that external exposure to these 
compounds through pharmacological or toxicological application to the body has the potential 
to alter various physiological and pathophysiological processes.60 As they are already 
postulated to be involved in the pathogenesis of certain diseased states, there is the further 
possibility that an environmental presence of these compounds may also pose an ecological 
threat. It has been proposed that IsoPs may result in “contagious”18 or “circular”54 toxicity, 
whereby exposure to these compounds through effluent release may cause the propagation of 
oxidative stress in nearby wastewater-receiving ecosystems. They could then stimulate 
numerous effects in an exposed organism (such as those outlined in Section 1.3.4), potentially 
resulting in additional oxidative stress and IsoP production, creating this so-called cycle. These 
effects will likely only be initiated if the organism possesses biomolecules with which IsoPs 
can interact. However, the role of IsoPs as potential ECs gains credibility when it is considered 
that many metabolic processes and receptors are phylogenetically conserved between species. 
For example, aquatic organisms have been found to possess prostanoid molecules and 
receptors,110, 111 while IsoPs have also been detected within aquatic organisms in association 
with lipid peroxidation.112, 113, 114 Given what is currently understood regarding their 
bioactivity, IsoPs are likely to exert some of their biological effects via this prostanoid receptor 
in aquatic species, as they do in others,54 resulting in a similar plethora of physiological 
impacts.  
 
To summarise, there are multiple factors which contribute to the emerging status of IsoPs as 
contaminants of concern, including: (I) They are bioactive compounds capable of inducing 
adverse effects; (II) Metabolic processes are conserved between species, meaning that it is 
likely that IsoP-biomolecule interactions will also be conserved in aquatic organisms, 
potentially allowing these effects to be induced at elevated IsoP concentrations; (III) They are 
excreted by humans and other animals, whereby they enter WWTPs and have the potential to 
be discharged into the environment; and (IV) Their continuous release means that there is the 
potential for pseudo-persistence in environmental matrices. This could result in chronic 
exposure for aquatic species, by which low levels over a long period of time could result in a 
continuous cycle of oxidative stress. Further research is required to determine the 
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concentrations of IsoPs in effluent and whether their presence can result in increases in their 





Figure 1-5. A conceptual diagram illustrating the roles of IsoPs as potential emerging contaminants. 
Solid lines: Represent understood biological pathways of IsoPs. Dashed lines: Represent the 
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1.6 Thesis objectives and layout  
1.6.1 Thesis objectives 
Isoprostanes are potential ECs of concern. Bioactive markers of oxidative stress, these 
compounds have been linked to various biological processes and diseases. The urinary 
excretion of IsoPs provides a mechanism for their entry to WWTPs, and potentially the wider 
environment through the discharge of wastewater. This investigation into IsoPs as potential 
ECs is part of a wider project affiliated with Professor Chris Metcalf at Trent University 
(Canada), who is currently conducting the first ecotoxicology studies on juvenile trout. This 
research aims to determine if WWTPs allow for the entry of IsoPs into the environment, 
through:   
1. Developing a method using SPE and GC-MS for the detection of IsoPs in wastewater 
influent, effluent and freshwater.  
2. Measuring the concentration of IsoPs present in wastewater influents and effluents from 
the Canterbury region.  
1.6.2 Layout  
Chapter 1 introduces the reader to the aims of this thesis and the research behind the theory of 
IsoPs as a new potential class of contaminants. In Chapter 2, the development and validation 
of a GC-MS method for the analysis of 15-F2t-IsoP into wastewater is described. Chapter 3 
provides a detailed summary of the sampling plan and the optimised analytical methods used 
in this study. The provisional results from a survey of Canterbury WWTPs are reviewed in 
Chapter 4, and finally Chapter 5 discusses the roles of IsoPs as potential ECs, the limitations 
of this research, and provides recommendations for future work.  
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Chapter 2 
Method Development and Validation 
2.1 Chemicals and materials  
All solvents used in this study were HPLC grade and purchased from Thermo Fisher Scientific. 
These included acetone, acetonitrile, hexane, iso-octane and methanol. Ultra-pure water (<18 
MQ) was sourced from an in-house Rephile Bioscience Ltd filtration system. The deionised 
water (DI) was also retrieved from an in-house filtration system. Vircon and Decon-90 were 
also purchased from Thermo Fisher Scientific.   
 
15-F2t-isoprostane (15-F2t-IsoP) and 15-F2t-isoprostane-D4 (D4-15-F2t-IsoP) were purchased 
from Cayman Chemical and stored at -20°C. All standards were made up in HPLC grade 
solvents, and purged with nitrogen following use. Step-wise dilutions were used to ensure that 
accurate concentrations were achieved. BG100 β-glucuronidase (Helix promatia) was 
purchased from Kura Biotec. Pentafluorobenzyl bromide (PFB-Br), diisopropylethylamine 
(DIPEA), diethylamine (DEA), chlorodimethyl(3,3,3-trifluoropropyl)silane (CDMTFS), 
ammonium iodide (NH4I), 2-mercaptoethanol, N,O-Bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) and N-Trimethylsilyl-N-methyl trifluoroacetamide (MSTFA) ( ≥ 98.5%) were 
purchased from Sigma Aldrich. The Whatman GG/C filter paper (1.2 um pore size, 47 mm 
diameter) were also purchased from Sigma Aldrich. Strata X-AW, Strata X and Strata Florisil 
pesticide grade (FLPR) cartridges (all 500mg/6mL) were purchased from Phenomenex, 
 
Solid phase extraction (SPE) was undertaken on a VacMaster Sample Procession Station 
(Biotage). The sample bottles were connected to the SPE cartridges through Teflon transfer 
tubes and end caps. Teledyne-ISCO 3700 portable samplers and PTFE bottles were borrowed 
from the Institute of Environmental Science and Research (ESR) for wastewater collection. 
The sampling stainless steel buckets (15 L) and mixer were purchased from Bunnings 
Warehouse. 
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2.2 The selection of 15-F2t-Isoprostane as the analyte of interest 
For the purpose of this research, the 15-F2t-IsoP isomer was investigated. This isomer was 
chosen due to its commercial availability and comparability to other literature methods, as it is 
one of the most commonly analysed IsoP isomers in biological matrices (e.g. urine and 
plasma).115, 116 IsoPs serve as proxies for each other,17 whereby for the purpose of this research, 
the analysis of 15-F2t-IsoP represents a proxy for the analysis of IsoPs in general and their 
potential concentrations in wastewater. 
2.3 Development of a derivatisation and analytical method for 
isoprostane analysis  
Initially, DIMETRIS, a recently developed derivatisation agent, was trialled to improve the 
detection of 15-F2t-IsoP through GC-MS analysis (Section 2.3.1). A series of the potential ions 
that may have formed were calculated while working with this agent, although ultimately none 
were found. Following which, the more commonly used derivatisation agent BSTFA was 
trialled alongside PFB-Br. Both BSTFA and MSTFA result in the esterification of a TMS 
(trimethylsilyl) group on to the analyte. Because there was no record in literature of MSTFA 
being used for IsoPs and the stability of the agent, it was introduced and trialled as an 
alternative agent for use alongside the PFB-Br (Section 2.3.2).  
2.3.1 Trialling DIMETRIS as a new derivatisation agent for isoprostanes 
Synthesis of DIMETRIS 
DIMTRIS (Figure 2-1) was synthesised following the methods of Caban et al. (2013).117, 118 
From a bulk solution, 2 mL of acetone:hexane (1:1, v/v) and 300 µl of DEA were pipetted into 
a glass centrifuge tube and mixed. Then 300 µl of CDMTFS was added, and the mixture 
vortexed for 5 minutes. Following this, the mixture was centrifuged for 15 minutes at 2500 
rpm, as recommended by Caban et al. (2013).117, 118 Due to only partial phase separation, the 
methods were adjusted, increasing the centrifuge time to 20 minutes. The pale, yellow 
supernatant was then transferred into reacti vials, flushed with N2 and refrigerated (4°C) until 
use. The agent could be stored for a week before degradation was a concern. 
 
 








Figure 2-1. (A) The structure of DIMETRIS and DMTFPS, its esterified form. (B) The fragmentation 
pattern of DMTFPS, resulting in m/z 171, 155 and 97 as the predominant ions. Adapted from Caban 
et al.(2013).117, 118 
 
Derivatisation of 15-F2t-Isoprostane with DIMETRIS 
As DIMETRIS was initially developed for the analysis of ethinylestradiol (EE2), derivatisation 
trials were conducted with both IsoP and EE2, so that the EE2 could be used to determine 
derivatisation success. First, 500 µl of 1 μg/mL IsoP or EE2 standard were transferred into 1 
mL reacti vials, and dried down under N2. 50 µl of synthesised DIMETRIS and 50 µl of toluene 
were then added, and the mixture vortexed for 1 minute. The solutions were then derivatised 
at 30°C for 30 minutes. The derivatised compounds were transferred into GC vials with 400 µl 
of iso-octane and analysed by the GC-MS. 
 
As no obvious peaks indicative of the IsoP compound were found, a series of the most likely 
ions formed, were calculated based on: (I) Potential sites of esterification (Figure 2-2); (II) how 
IsoP molecules fragment in literature (Figure 2-3); (III) how IsoPs fragment with alternative 
derivatisation agents (Table 2-1); and (IV) the most likely number of esterification’s of 
DIMETRIS 
M = 227 
DMTFPS 
M = 155 
A 
B 
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DIMETRIS onto the IsoP (Figure 2-4, Table 2-2). In addition to searching for these ions within 
previous chromatograms, multiple series of these ions were also targeted using selected 
ionisation mode (SIM) on the GC-MS (summarised in Table 2-3). Other parameters were also 
adjusted. These included, increasing the incubation time to 45 minutes, trialling higher 
concentrations of IsoP, increasing the ion source temperature and MS temperature profile. The 
latter two parameter changes were deemed necessary due to the high predicted mass (660-970) 
of the esterified parent IsoP compound, which may have affected its volatilisation.119 
 
 
Figure 2-2. Potential sites for esterification of derivatisation agents to 15-F2t-IsoP (A, B, C and D). 
 
 
Figure 2-3. Potential fragmentation patterns of 15-F2t-IsoP through GC-MS analysis (Based on 
Morrow et al. (1990)).41 
 
 











Table 2-1. The mass fragments most likely to be formed based on the behaviour and ionisation patterns 
observed through the GC-MS analysis of IsoP(TMS)3 (Based on Tsikas et al. (1998)95)*. 
*Based on literature, it is assumed that (A, C, and/or D) are derivatised primarily over (B). i.e. (B) is 
only derivatised when the IsoP molecule has been derivatised 4 times. 
P = Parent compound; D = DMTFPS; DOH = DMTFPS and a hydroxyl group; and Deriv = Number of 








D = DMTFPS 4 x Deriv 3 x Deriv 2 x Deriv 1 x Deriv 
DOH 171 171 171 171 
D 155 155 155 155 
P 970 815 660 505 
P-DOH-D 644 489 334 179 
P-2DOH-D 473 318 - - 
P-3DOH-D 302 - - - 
P-2DOH-2D 318 - - - 
P-3DOH-D-CO2 258 - - - 
P-2DOH-D-CO2 429 274 - - 
P-3DOH-CO2 413 258 - - 
P-2DOH-CO2 584 429 274 - 
P-DOH-CO2 755 600 445 290 
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Derivatised 4 times with 
DMTFPS 
970 = M 






























(A, B, C, D)
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Derivatised 2 times with 
DMTFPS 









Figure 2-4 continued. The structure of 15-F2t-IsoP derivatised 2-4 times at different sites 
on molecule. 
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Table 2-2. A condensed list of the potential ions which may form during GC-MS analysis of 15-F2t-
IsoP(DMTFPS)n. This is based on the potential number of esterification’s with DMTFPS (altering 
parent M) and fragment patterns of 15-F2t-IsoP (loss of I, II, and III). 
Parent ion I II III 
970 = M (A, B, C, D) (A, B, C, D) (A, B, C, D) 
 592 = M – 281 – 97 618 = M – 255 – 97 802 = M – 71 – 97  
 534 = M – 281 – 155 560 = M – 255 – 155 744 = M – 71 – 155  
 518 = M – 281 – 171 544 = M – 255 – 171 728 = M – 71 – 171 
 491 = M – 281 – 194 521 = M – 255 – 194 705 = M – 71 – 194  
 379 = M – 281 – 310 405 = M – 255 – 310 589 = M – 71 – 310  
 347 = M – 281 – 342 373 = M – 255 – 342 557 = M – 71 –342 
 398 = M – 281 – 291 424 = M – 255 – 291 608 = M – 71 – 291 
 224 = M – 281 – 465 250 = M – 255 – 465 434 = M – 71 – 465  
 176 = M – 281 – 513 202 = M – 255 – 513 386 = M – 71 – 513  
 301 = M – 281 – 388 327 = M – 255 – 388 511 = M – 71 – 388  
 69   = M – 281 – 620  95   = M – 255 – 620 279 = M – 71 – 620 
 5     = M – 281 – 684 31   = M – 255 – 684 215 = M – 71 – 684  
815 = M      
 
(A, B, C), (A, B, D) 
and (B, C, D) 
(A, B, D), (A, C, D) 
and (B, C, D) 
(A, B, C), (A, B, D), (A, 
C, D) and (B, C, D) 
 437 = M = 281 – 97  463 = M – 255 – 97 647 = M – 71 – 97  
 379 = M = 281 – 155  405 = M – 255 – 155  589 = M – 71 – 155 
 363 = M – 281 – 171  389 = M – 255 – 171   573 = M – 71 – 171  
 340 = M – 281 – 194  366 = M – 255 – 194  550 = M – 71 – 194 
 224 = M – 281 – 310  250 = M – 255 – 310  434 = M – 71 – 310  
 192 = M – 281 – 342  218 = M – 255 – 342  402 = M – 71 – 342 
 243 = M – 281 – 291  269 = M – 255 – 291  453 = M – 71 – 291  
 69  = M – 281 – 465  95  = M – 255 – 465  279 = M – 71 – 465 
 21  = M – 281 – 513  47  = M – 255 – 513  231 = M – 71 – 513 
 (A, C, D) (A, B, C) - 
 592 = M – 126 – 97 618 = M – 100 – 97  - 
 534 = M – 126 – 155  560  = M – 100 – 155 - 
 518 = M – 126 – 171  544  = M – 100 – 171 - 
 495 = M – 126 – 194  521  = M – 100 – 194 - 
 379 = M – 126 – 310  405  = M – 100 – 310 - 
 347 = M – 126 – 342 373  = M – 100 – 342 - 
 398 = M – 126 – 291  424  = M – 100 – 291 - 
 224 = M – 126 – 465  250  = M – 100 – 465 - 
 176 = M – 126 – 513  202  = M – 100 – 513 - 
    
    









    
660 = M    
 
(A, B), (B, C)  and (B, 
D)  
(A, B), (B, C) 
(A, B), (B, C), (A, D), 
(C, D) and (B, D) 
 282 = M – 281 – 97 463 = M – 100 – 97  492 = M – 71 – 97  
 224 = M – 281 – 155  405 = M – 100 – 155 434 = M – 71 – 155 
 208 = M – 281 – 171 389 = M – 100 – 171 418 = M – 71 – 171  
 185 = M – 281 – 194  366 = M – 100 – 194  395 = M – 71 – 194  
 69 = M – 281 – 310  250 = M – 100 – 310  279 = M – 71 – 310  
 37 = M – 281 – 342  218 = M – 100 – 342  247 = M – 71 – 342  
 
(A, C), (A, D) and (C, 
D) 
(A, D), (C, D) and (B, 
D) 
- 
 437 = M – 126 – 97  308 = M – 255 – 97  - 
 379 = M – 126 – 155  250 = M – 255 – 155  - 
 363 =  M- 126 – 171  234 = M – 255 – 171  - 
 340 = M – 126 – 194  211 = M – 255 – 194  - 
 224 = M – 126 – 310  95 = M – 255 – 310  - 
 192 = M – 126 – 342  63 = M – 255 – 342  - 
 176 = M – 126 – 513  202  = M – 100 – 513 - 
 
(A, B), (B, C)  and (B, 
D)  
(A, B), (B, C) 
(A, B), (B, C), (A, D), 
(C, D) and (B, D) 
 282 = M – 281 – 97 463 = M – 100 – 97  492 = M – 71 – 97  
 224 = M – 281 – 155  405 = M – 100 – 155 434 = M – 71 – 155 
 208 = M – 281 – 171 389 = M – 100 – 171 418 = M – 71 – 171  
 185 = M – 281 – 194  366 = M – 100 – 194  395 = M – 71 – 194  
 69 = M – 281 – 310  250 = M – 100 – 310  279 = M – 71 – 310  
 37 = M – 281 – 342  218 = M – 100 – 342  247 = M – 71 – 342  
 
(A, C), (A, D) and (C, 
D) 
(A, D), (C, D) and (B, 
D) 
- 
 437 = M – 126 – 97  308 = M – 255 – 97  - 
 379 = M – 126 – 155  250 = M – 255 – 155  - 
 363 =  M- 126 – 171  234 = M – 255 – 171  - 
 340 = M – 126 – 194  211 = M – 255 – 194  - 
 224 = M – 126 – 310    95 = M – 255 – 310  - 
 192 = M – 126 – 342    63 = M – 255 – 342  - 
Chapter 2: Method Development 
 
 32 
GC-MS method parameters and analysis 
The basic GC-MS instrumental parameters were set according to those described at the 
beginning of Section 3.2.3.3. Additional parameters were trialled and altered over time to 
enable the detection of the ions (Table 2-3). Following analysis in SCAN mode, all of the 
calculated potential ions were searched for within the final chromatograms. Additionally, blank 
versus standard (1 μg/mL 15-F2t-isoP) chromatograms were compared to see if an obvious peak 
representative of 15-F2t-IsoP could be identified manually. Ions representative of the EE2 
compound were found, but despite this, 15-F2t-IsoP could not be identified with this 
derivatisation agent. To ensure that the lack of identification was not due to a fault with the 
IsoP standard, the standards were also run on a mass spectrometer to confirm their identity. 
Ultimately, due to time restrictions an alternative derivatisation method was trialled (Section 
2.3.2).  
 
Table 2-3. GC-MS instrumental parameters for different methods trialled to enable the detection of the 
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2.3.2 Trialling PFB-Br and BSTFA or MSTFA as derivatisation agents 
2.3.2.1 Derivatisation with PFB-Br and BSTFA or MSTFA 
Following the derivatisation trials with DIMETRIS, PFB-Br and BSTFA were then 
investigated as they are commonly used in literature for the identification of IsoPs. Methods 
for PFB-Br and BSTFA derivatisation were based on those prescribed in literature.94, 102, 120 All 
of the reagents were anhydrous and purged with N2 following each use then stored in 
desiccators to reduce moisture contamination. Small volumes of the solvents were sourced 
from the in-house dry solvent system each day before use. The iso-octane was dried through 
treatment with solvent washed (3 x rinsed with each of methanol, acetonitrile and acetone) 
anhydrous sodium sulphate each day and stored in a desiccator.  
 
Initially, 500 μL aliquots of a 1 μg/mL 15-F2t-IsoP standard were transferred into reacti vials 
and dried down under N2. 100 μL of anhydrous acetonitrile was then added to the samples and 
derivatisation agent blanks. These were then mixed before 10 μL of methanol followed by 10 
μL of PFB-Br and DIPEA were also added. The vials were then incubated at 30°C for 60 
minutes. Following cooling, the mixtures were evaporated under N2. 30 μL of BSTFA, BSFTA 
+ TMS (99:1) or MSTFA (see Section 3.2.3.1 for synthesis) were added to the vials, and they 
were incubated for an additional 60 minutes at 60°C. Once cooled to room temperature, the 
samples were quantitatively transferred into amber glass GC vials with 2 x 250 μL anhydrous 
iso-octane and stored at 4°C. 
GC-MS methods and analysis 
Based on the literature, m/z 569 was set as the desired quantifier ion to target 15-F2t-IsoP 
(Figure 2-5). Both SCAN and SIM modes were used to identify the ion, however no peaks 
indicative of the ion were observed. New PFB-Br and catalyst were also trialled, as it was 
concluded that this esterification processes was most likely the stage of the reaction that was 
not working as expected, but this still did not result in finding the ion. Multiple different 
instrumental parameters were also trialled in order to accurately identify the compound (Table 
2-4). These included altering the temperature profile and searching for alternative ions that 
appeared in the SCAN chromatograms of the samples versus blanks (Table 2-4, Method P-2a).  
Reactions with or without the presence of PFB-Br or the catalyst were also conducted. Through 
these trials, a different peak and series of ions were identified that were linked to the formation 
of 15-F2t-IsoP-(TMS)4, leading to the conclusion that the initial PFB esterification reaction was 
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not occurring. The 15-F2t-IsoP(TMS)4 formation was confirmed through a similarity search of 
a standard and derivatisation agent blank, identifying m/z 391, 462, 481, 537, 552, 571, 627 as 
likely being representative of the compound. Further method development on the basis of these 








Table 2-4. GC-MS instrumental parameters for the different methods trialled to enable the detection of 



























































Chapter 2: Method Development 
 
 35 
2.3.2.2 Optimising the derivatisation reaction with either MSTFA or BSTFA to 
  form 15-F2t-IsoP(TMS)4 
Both MSTFA and BSTFA were trialled as derivatisation agents to produce 15-F2t-IsoP(TMS)4. 
MSFTA was selected for further method development due to the reliable stability of the 
samples following derivatisation. Their relative stabilities were determined by analysing 
standards of 1 μg/mL and 0.1 μg/mL 15-F2t-IsoP derivatised with either BSTFA or MSTFA 
daily for a week and comparing the changes in signal intensity. While the general working 
concentration of 15-F2t-IsoP was 1 μg/mL to ensure optimisation of the derivatisation methods, 
a 10 point calibration curve was also formed with different concentrations of 15-F2t-IsoP (1-
1000 ng/mL) to ensure linearity. To derivatise the compounds, aliquots of the IsoP standards 
were dried down in reacti vials and 30 μL of the MSTFA mix was added. Following mixing, 
the standards were incubated for 45 minutes at 65°C. Once cooled, the samples were then 
transferred into 200 μL GC vial inserts, and made up to either 100 μL or 200 μL with iso-
octane and analysed by GC-MS. Ultimately the final volume of 200 μL was selected to improve 
the transfer of the derivatised analytes into the GC vials.  
GC-MS methods and analysis 
Multiple instrumental parameters (Table 2-5) were trialled before method M-1c was selected 
as an optimised method which could then be carried through to other stages of the method 
development (extraction, deconjugation, quantifying internal standard and surrogate). While 
other ions had been identified as being representative of 15-F2t-IsoP, they were also formed as 
a result of the derivatisation agent and were not used as qualifier ions in case they resulted in 
the false detection of the analyte. The initial oven temperature was held at 140°C for 4 minutes, 
then increased at a rate of 18°C/minute to 300°C. It was held for an additional 4 minutes, then 
increased to 310°C, at a rate of 20°C/minute. The samples were injected at a temperature of 
250°C, the ion source held at 200°C and the interface at 310°C. The m/z 391 was used as the 
quantifier ion, while 481 and 537 were used as the qualifiers (Figure 2-6). The retention time 
of the 15-F2t-IsoP(TMS)4  ions were 13.62 minutes, although the GC-MS instrumental 
parameters were later adjusted to allow for a longer temperature profile in order to separate 
interferences caused by the deconjugation agent which occurred at the retention time of the 













Table 2-5. GC-MS instrumental parameters for different methods trialled to enable the detection of the 
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Figure 2-6. Derivatisation of 15-F2t-IsoP with MSTFA, and the subsequent formation of the quantifier 
(m/z 391) and qualifier (m/z 481 and 537) ions used for identification. 
 
2.4 Filtration, deconjugation and solid phase extraction development 
2.4.1 Filtration 
Initially, due to the small volume (200 mL) of wastewater being used, extraction was trialled 
without vacuum filtration. But due to the clogging of the SPE cartridges, filtration was 
introduced. For each sample, a 500 mL aliquot of wastewater effluent was defrosted then 
adjusted to pH 5 with acetic acid to ensure they were at the optimum pH for the deconjugation 
reaction (Section 2.4.2). The samples were vacuum filtered through solvent cleaned GF/C 47 
mm filter papers. When working with influent, only 100 mL was measured and filtered per 
filter paper to ensure efficiency. In comparison, 200 mL of effluent could be filtered per filter 
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with an additional 20 mL ultrapure water and allowed to flow through. The filter papers were 
then dried and stored on methanol rinsed tinfoil in the freezer. Following filtration, the pH was 
checked again, and if required extra acetic acid was added.  
2.4.2 β-glucuronidase deconjugation method development 
Method Development 
As a large proportion of 15-F2t-IsoP molecules are excreted as glucuronide conjugates, 
deconjugation treatment can significantly increase the concentrations available for detection 
(Section 1.4.1).105, 106 Deconjugation was conducted following the filtration of the wastewater 
samples. The deconjugation trials were run alongside each extraction trial (Section 2.4.3), 
starting with Trial 1 (Section 2.4.3.1). To ensure comparability, every trial was set up as 
outlined in Table 2-6, and the respective sample codes are applied throughout the rest of this 
chapter. The wastewater was split into 4 x 200 mL aliquots for each SPE cartridge type, while 
an additional 2 x 200 mL DI was also prepared. The glucuronidase enzyme was then assessed 
in: (I) Spiked wastewater (SW-En); (II) unspiked wastewater (W-En); (III) Spiked DI (SDI-
En); and (IV) unspiked DI (DI-En) (Table 2-6). Two additional aliquots of 200 mL wastewater 
were also extracted without the addition of the enzyme to determine the degree of interference 
from the enzyme during the extraction procedure and analysis (SW and W). Once the 
wastewater had been separated into aliquots, 1.5 mL of β-glucuronidase was added to the 
appropriate samples (Table 2-6). These were then placed in a water bath and incubated at 37°C 
for 2 hours.105, 106, 122 Once cooled, these samples were spiked with the surrogate and run 
through the extraction trials (Section 2.4.3). 
GC-MS analysis and results 
GC-MS analysis was conducted following the method M1c, above (Section 2.3.2.2, Table 2-
5). The presence of β-glucuronidase resulted in a peak at a very similar retention time to the 
analyte, so to separate their retention times, the temperature profile was adjusted from a rate of 
18°C/minute from 140°C to 300°C, to 16°C/minute. As a result, the IsoP retention time 
increased to 14.5 minutes and could be better quantified in the presence of the deconjugation 
agent. However, this temperature profile was subsequently adjusted again to attempt to separate 
some of the matrix effects in the following trials (Section 2.4.3.1).  
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Table 2-6. A representation of the minimum number of sample-types run for each extraction trial. This 
allowed the effects of the matrix on the recoveries and reproducibility to be determined and compared 










(200 µl 0.1 µg/mL) 
Surrogate 
D4-15-F2t-IsoP 
 (200 µl 0.1 µg/mL) 
SW-En Wastewater ✓ ✓ ✓ 
W-En Wastewater ✓ ✕ ✓ 
SW Wastewater ✕ ✓ ✓ 
W Wastewater ✕ ✕ ✓ 
SDI-En Deionised water ✓ ✓ ✓ 
DI-En Deionised water ✓ ✕ ✓ 
*DI = Deionised water; En = Enzyme; S = Spiked; and W = Wastewater 
2.4.3 Extraction method development 
2.4.3.1 Trial 1: A comparison between SPE cartridges 
Trial 1: Methods 
The first SPE extraction trial consisted of a comparison between the recoveries of Strata X and 
Strata X-AW cartridges. Although both have been used in the literature, the former was 
selected as it is commonly used within our research laboratory and in the literature for the 
efficient extraction of polar analytes in environmental samples. The latter was selected as it 
commonly provides good clean-up efficiency and recoveries for IsoPs in biological samples.100 
As noted previously (Table 2-6), the wastewater and DI were split into 200 mL aliquots for the 
extraction trials. Following the deconjugation treatment, 200 μL of the D4-15-F2t-IsoP (0.1 
μg/mL) surrogate was added to every sample. Then 200 μL of 15-F2t-IsoP (0.1 μg/mL) native 
was added to 3 aliquots for each cartridge type, representative of: (I) DI spike; (II) wastewater 
+ enzyme spike; and (III) wastewater spike. A comparative for recovery analysis was also 
dispensed with 200 μL of the 0.1 μg/mL surrogate-native standard mix in 10 mL acetone. 
 
Each cartridge (6 x Strata X and 6 x X-AW) was conditioned prior to extraction. First, 3 x 5 
mL acetone was allowed to flow through under gravity. Once half the solvent was through, the 
flow was stopped for 2 minutes, then continued. This process was repeated with methanol and 
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ultrapure water. Finally, ultrapure water was added a fourth time, and left to sit covered with 
methanol-rinsed tinfoil until the samples were loaded. The samples were then loaded and 
passed through either the Strata X or X-AW cartridges, before being dried under a vacuum for 
2 hours. Prior to elution, the cartridges were stacked above previously-used Strata FLPR 
cartridges filled with solvent-rinsed anhydrous sodium sulfate. Next, 5 mL of acetone was 
added to the top Strata X or X-AW cartridges and allowed to drip halfway through, then sit for 
2 minutes to saturate the SPE bed and eluted. This was repeated an additional 5 times, bringing 
the total eluent volume to 30 mL. The samples were dried down to ~0.5 mL, and quantitatively 
transferred into reacti vials, with 2 x 250 μL acetone. These and the comparative standard were 
then dried down under a gentle stream of N2 at 40°C for derivatisation with MSTFA (Section 
3.3.3 for finalised method). 
Trial 1: GC-MS analysis and results 
The samples were analysed using the GC-MS instrumental parameters specified in Section 
2.4.2. To account for the matrix interferences, the temperature profile was adjusted again to a 
slower rate of increase. The GC-MS temperature profile was initially held for 4 minutes at 
140°C, then increased at a rate of 8°C/minute to 300°C. It was then increased to 310°C at 
20°C/minute, and held for an additional 5 minutes. The retention time of the analytes became 
21.795 and 21.792 minutes for 15-F2t-IsoP and D4-15-F2t-IsoP respectively. While this change 
did provide some improvement, the recoveries were still too low with very poor 
reproducibility, meaning the extraction procedures required more adjustment before further 
clean-up steps could be trialled.  
 
Initially, the cartridges were dried for 2 hours once the samples had been loaded. To ensure 
that moisture contamination was not contributing to the recovery inconsistencies, the drying 
time was increased to 2.5 and 3 hours which still did not improve the recoveries. The DI-
enzyme blank (DI-En) also indicated that the enzyme caused a low level of interference at the 
retention time of the analytes (Figure 2-7, DI-En). The recovery and reproducibility values 
were variable for both the DI and the wastewater samples, the wastewater especially resulting 
in significant matrix effects. The recoveries ranged from 0-60%, with the lower values being 
the more dominant. Additionally, many peaks were unable to be accurately integrated due to 
the presence of interfering peaks, inaccurate ion ratios and low signal to noise ratios (S/N < 
2.5) (Figure 2-7).  
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* * * 
15-F2t-IsoP D4-15-F2t-IsoP 15-F2t-IsoP D4-15-F2t-IsoP 
Figure 2-7. Chromatogram retention windows representative of 15-F2t-IsoP and D4-15-F2t-IsoP, under different conditions and extracted through either 
Strata X or X-AW cartridges. Shown above are the results for the extraction of SW-En, W-En and DI-En. *Denotes results where the native or surrogate 
was not detected due to inaccurate ion ratios, low signal-to-noise ratios or interfering peaks. An arrow is used to depict the location of the IsoP peak. 
SW-En = Spiked wastewater with enzyme; W-En = Wastewater with enzyme; and DI-En = Deionised water with enzyme. 



















































































S/N  2.6 S/N 14.87 S/N 3.56 S/N 2.13 
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2.4.3.2 Trial 2: Refining the extraction method 
Trial 2: Methods 
The next trial focused on the Strata X-AW cartridges with the addition of an acidic pre-
conditioning step, alongside a comparison between methanol or acetone elution, based on the 
methods of Taylor et al. (2008).103 First the samples were filtered and deconjugated as 
described above (Table 2-6). The cartridges were then pre-conditioned with 3 x 5 mL acetone. 
Following this, 3 x 5 mL of methanol:acetic acid (98:2, v/v) was run through, followed by 5 
mL ultrapure water. Each solvent was allowed to flow through under gravity, until half was 
gone, before the flow was stopped again to allow the solvents to permeate the SPE bed. 
Following the ultrapure water, an additional 5 mL of water was added to prevent the SPE bed 
from becoming exposed to air. The samples were then loaded and allowed to dry for 2.5 hours. 
Following this they were stacked above the sodium sulfate FPLR cartridges and eluted with 
either 6 x 5 mL methanol or acetone, as described above. Two comparatives were also made 
up prior to extraction with 200 μL of a 0.1 μg/mL surrogate-native standard mix in either 10 
mL acetone or methanol. The samples and comparatives were then dried down at 40°C, and 
derivatised with MSTFA.  
Trial 2: GC-MS analysis and results 
The GC-MS parameters developed in Trial 1 (Section 2.4.3.1) were used for the remaining 
trials. Elution with methanol was selected for further method development as it was found to 
provide better recoveries and more reproducible results in comparison to acetone (Table 2-7, 
Figure 2-8). The enzyme, as well as other interfering substances, continued to result in low 
levels of interference that could not be removed through adjusting the temperature profiles to 
try to separate their retention times from those of the IsoPs. Matrix effects were also prominent 
issues in the wastewater samples and impacted the reliability of peak integration by altering 
the ion ratios. While many of the interferences were variable between samples and treatment 
plants, Bromley wastewater samples consistently had a trialling peak, with a m/z of 395, which 
interfered with the detection of the surrogate. A similarity search in SCAN did not yield any 
suggestions as to what the interfering substance could have been, although some of the 
interfering substances which were identified included eicosanoic acid, pentacosanoic acid 
glycerol and androsterone. As a result it was deemed necessary that further sample clean-up 
would be required to remove some of these compounds and other unknown interferences.  
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Table 2-7. A comparison between the extraction efficiencies of 15-F2t-IsoP and D4-15-F2t-IsoP spiked into either wastewater or DI and eluted with either 
methanol (MeOH) or acetone (Ace). 
Data Sample SW-En-MeOH SW-En-Ace W-En-MeOH W-En-Ace* SDI-MeOH SDI-Ace DI-En-MeOH DI-En-Ace 
15-F2t-
IsoP 
Avg.R (%) 83.2 0.3 8.5 ND 39.9 2.5 6.3 ND 
SD 66.7 0.4 14.8 - 33.3 3.6 1.2 ND 
D4-15-
F2t-IsoP 
Avg.R (%) 81.1 1.3 89.6 76.6 44.1 ND 74.2 14.2 
SD 50.5 1.9 17.1 - 38.4 ND 45.4 20.1 
*Only have data for one series of trials. All others were repeated 2-3 times.  












































































* * * * 
15-F2t-IsoP D4-15-F2t-IsoP 
Figure 2-8. Chromatogram comparisons for native (15-F2t-IsoP) and surrogate (D4-15-F2t-IsoP) spikes in wastewater and DI, using either methanol or acetone 
to elute the compounds. Of which, methanol elution provided better analyte recoveries. (A) SW-En eluted with methanol; (B) SDI-En eluted with methanol (C) 
SW-En eluted with acetone; and (D) SDI-En eluted with acetone.*Represents no peak or incorrect ion ratios. 




S/N 13.71 S/N  14.01 S/N  25.89 S/N 18.83 
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2.4.3.3 Trial 3: Sample purification  
The next series of method development trials focused on introducing a clean-up strategy 
following sample extraction. Both florisil cartridges and silica gel chromatography were 
trialled.  
Florisil methods and results 
For the florisil trial, sample preparation (filtration, deconjugation, and loading of samples onto 
Strata X-AW cartridges) was conducted following the aforementioned methods (e.g. Section 
2.4.3.2). The elution differed from previous methods as the sodium sulfate was placed into 
new, unused FL-PR cartridges, before it was pre-conditioned with 3 x 5 mL acetone. The 
samples were then eluted with methanol as in Trial 2, dried down, derivatised and analysed. 
The results suggested that although florisil removed many of the interfering substances and 
other contamination within the samples, it also resulted in significant loss of analyte as no 
native or surrogate 15-F2t-IsoP could be detected through GC-MS analysis (Figure 2-9).  
Silica gel chromatography methods and results  
The first investigation using silica gel chromatography focused on determining the recoveries 
of the native and surrogate IsoPs using methods adapted from Milatovic et al. (2011).123 First, 
a small volume of glass wool was packed into the glass column. Around 0.55 g of silica gel 
was then loaded onto the wool and 5 x 1 mL ethyl acetate was used to condition the silica gel, 
while a pipette bulb was used to expunge the remaining solvent. A spike (200 µl of a 0.1 µg/mL 
native and surrogate mix) and blank in 1 mL methanol were then prepared and loaded onto two 
separate silica columns. They were allowed to drip through then the remaining moisture was 
removed through forcing it out with a pipette bulb. Because Milatovic et al. (2011)123 used a 
wash step prior to elution, this was also trialled. Following sample loading, 5 x 1 mL of the 
ethyl acetate wash was loaded onto the column. The wash was collected in a 5 mL reacti vial 
for analysis as it was suspected that the ethyl acetate would have resulted in the elution of the 
analytes due to its polarity. Following this, 5 x 1 mL ethyl acetate:methanol (50:50 v/v) was 
used to elute the compounds and was collected in 5 mL reacti vials. The extracts were then 
dried down under nitrogen, derivatised and analysed. A 70% recovery of both the native and 
surrogate in the wash solvent, compared to <1% in the elution solution suggested that the 
compounds were being eluted during the wash. It was concluded that the wash would not be 
included in the methods, and instead once the samples had been loaded, they would be eluted 
with the ethyl acetate:methanol mix. 







Florisil Silica Gel 
15-F2t-IsoP D4-15-F2t-IsoP 15-F2t-IsoP D4-15-F2t-IsoP 
Figure 2-9. A comparison between the chromatograms of 15-F2t-IsoP and D4-15-F2t-IsoP purified through either florisil or silica gel 
chromatography. *Denotes results where the native or surrogate were not detected due to inaccurate ion ratios, low signal to noise ratios or 
interfering peaks. An arrow is used to depict the location of the IsoP peak. 
SW-En = Spiked wastewater with enzyme; W-En = Wastewater with enzyme; and DI-En = Deionised water with enzyme. 































































































S/N 22.08 S/N 7.46 
S/N 3.62 





















The silica gel trial was then repeated using wastewater. Extraction was conducted following 
the outlined methods with methanol (Section 2.4.3.2). Following their elution from the SPE 
cartridges, the samples were dried down under N2 at 40°C to 0.5 mL. They were then 
transferred onto the pre-conditioned silica gel column with 2 x 250 µL methanol, allowed to 
run through, and then the analytes were eluted with 5 x 1 mL ethyl acetate:methanol (50:50, 
v/v) into 5 mL reacti vials. Again, these were dried down at 40°C under N2 and derivatised 
with MSTFA.  
 
The silica clean-up step was found to result in more reproducible results, while also removing 
some of the interferences present in the wastewater, specifically at the retention time of the 
analyte and surrogate (Figure 2-9, Figure 2-10). However, the significant trailing peak 
remained present in the majority of Bromley samples, meaning many were unable to be 
accurately integrated. Unfortunately, the silica gel column also a caused loss of surrogate and 
analyte (Table 2-8). However, overall, the recoveries were relatively consistent, other than in 
the Bromley samples which skewed the averages and increased the standard deviation of the 
results. Although there was room for the improvement of the methods, due to time constraints 
silica gel chromatography alongside Strata X-AW extraction was selected for sample analysis. 
 
Table 2-8. Mean recovery for native (based on spiked samples), and surrogate (based on samples and 
samples spikes). 
Analyte Mean Recovery ± SD (%) 
15-F2t-IsoP 46.4 ± 27.2 
D4-15-F2t-IsoP 43.1 ± 26.9 
 
2.4.3.1 Trial 4: Liquid-liquid extraction with hexane 
In a final attempt to clean-up the wastewater and provide better extractions, hexane liquid-
liquid extraction was trialled near the end of sample analysis. Because hexane is non-polar, it 
can be used to remove other non-polar interferences, including fats and lipids, from samples.  
As most of the samples had already been analysed, only the influent and a small volume of 
effluent was available to trial this method.124   
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 S/N 12.01 







 S/N 12.10 








Figure 2-10. A comparison between Trial 2 and Trial 3 chromatograms of Kaiapoi and Bromley effluent samples. *Denotes results where the native 
or surrogate were not detected due to inaccurate ion ratios, low signal to noise ratios or interfering peaks. An arrow is used to depict the location of 
the IsoP peak.  




15-F2t-IsoP D4-15-F2t-IsoP 15-F2t-IsoP D4-15-F2t-IsoP 
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Firstly, 5 mL of hexane was added to 30 mL of methanol (the eluted volume), thoroughly 
homogenised, and then left to allow for layer separation. However, because the ratio between 
the two solvents was too large, the sample had to be left overnight for only partial phase 
separation. Instead, a methanol:hexane ratio of 1:1 or 2:1 was determined to be the optimal 
volumes of each solvent which allowed for rapid density separation while also maintaining 
enough liquid to safely remove the hexane layer. Following elution from the extraction 
cartridges, the solvent was dried under N2 to 5  mL and then a 5 mL aliquot of hexane was added. 
The amber glass vial was then thoroughly mixed through inversion and left to sit for 5 minutes. 
The upper hexane layer was then carefully removed without disturbing the methanol layer. The 
process was repeated with an additional 2 x 5 mL of hexane. Following this, the methanol was 
dried down to ~0.5 mL, and transferred into a reacti vial for derivatisation with MSTFA.  
Hexane trial: GC-MS and results.  
The GC-MS methods used were the same as previously mentioned (Section 2.4.3.1). The 
hexane clean-up technique appeared to improve spike recoveries while providing a similar 
clean-up efficiency to the silica gel chromatography (Table 2-9). A full comparison between 
the hexane and silica gel chromatography clean-up strategies could not be conducted due to a 
shortage of wastewater samples. Although, based on these preliminary results, it is likely that 
had this method been available prior to the effluent extractions, it would have further improved 
the recoveries and reproducibility of both the effluent and influent results. In future, it would 
be important to conduct repeated trials with wastewater from the same plant to determine the 
reproducibility of the method and the additional steps which could be undertaken to further 
clean-up the wastewater samples. Unfortunately, the hexane was unable to remove the 
interferences associated with the Bromley wastewater, which in the influent samples severely 
impacted the quantification of the surrogate concentrations in many samples, consequently 
decreasing the proportion of values which could be accepted. Table 2-10 presents a summary 
of the extraction and clean-up trials, specifying the optimal methods.  
 
Table 2-9. Mean recovery for native (based on spiked samples), and surrogate (based on samples and 
samples spikes) effluent samples through hexane clean-up. 
Analyte Mean Recovery ± SD (%) 
15-F2t-IsoP 146.1 ± 45.8 
D4-15-F2t-IsoP 56.0  ±  47.2 
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2.5 D4-15-F2t-Isoprostane surrogate and internal standard  
Following the initial extraction trails, D4-15-F2t-IsoP was introduced as a surrogate to be spiked 
into the samples prior to extraction to determine analyte recoveries (Figure 2-11). A series of 
ions were selected based on those used for 15-F2t-IsoP and those outlined in Bessard et al. 
(2001)76 to identify D4-15-F2t-IsoP. First, m/z 395 was chosen as the quantifier ion, then m/z 
485 and 541 as the qualifier ions. A MSTFA blank, 1 µg/mL derivatised D4-15-F2t-IsoP 
(surrogate), and 1 µg/mL derivatised D4-15-F2t-IsoP with 1 µg/mL 15-F2t-IsoP (native and 
surrogate) were then run to ensure that there were no interferences between the MSTFA and 
D4-15-F2t-IsoP, or between the surrogate and the native. 




Next, BPC (Bisphenol C) was introduced as an internal standard to account for derivatisation 
and injection efficiency. Mass to charge ratios of m/z 385 and m/z 386 and 400 were used as 
the quantifier and qualifier ions, respectively. A derivatisation agent blank and a 0.1 µg/mL 
BPC standard were run and compared to identify the retention time of the compound (17.615 
minutes) and to confirm that the BPC did not cause any interferences with the surrogate or 
native IsoP.  
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Chapter 3 
Optimised Sampling and Analytical Methods 
3.1 Wastewater sampling: Protocol and sample collection 
3.1.1 Wastewater treatment plants and sampling plan  
The WWTPs were selected based on several factors which allowed for a greater representation 
of urban, rural and industrial waste, as each source can contribute different volumes of 
wastewater and classes of contaminants.125 The different locations of these WWTPs around the 
Canterbury region ensured that there was a degree of variation between the size of the 
populations each plant serves, and the types of waste being processed (See Section 4.1). Initial 
communication with representatives from the WWTPs was aided by Mike Bourke from 
Christchurch City Council. Each plant was visited prior to sampling for safety inductions and 
to assess the most appropriate sites to set up the samplers.  
 
Temporal characterisation of the four WWTPs (Bromley, Governor’s Bay, Kaiapoi and 
Lyttleton) began in June (Figure 3-1). Both weekend and weekday 24 hour composite samples 
were collected to account for any potential differences in waste composition over a 7 day 
period. To ensure that the effluent was representative of the influent, the beginning of the 24 
hour sample collection was staggered based on the retention time of the plant (Table 3-1). 
Following this, three WWTPs (Bromley, Kaiapoi, and Lyttleton) were to be sampled monthly 
for 6 months. Initially, Ashburton was also to planned to be sampled during the temporal 
characterisation phase. However, as a result of sampler failures, time restrictions and the long 
(>30 days) retention time of the plant, it was removed from the sampling plan. During 
September, the 6 month plan was also changed so that solely effluent samples were collected 
and analysed every second month (August, October and December) to ensure adequate time 
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WWTP Retention time 
Time delay between influent and 
effluent sampling 
Bromley 4-5 hours 5 hours 
Governors Bay 24 hours 24 hours 
Kaiapoi 48 hours 48 hours 
Lyttelton 24 hours 24 hours 
Figure 3-1. Wastewater treatment plant locations within Canterbury. Map designed on 
Canterbury Maps. 
Information has been derived from various organisations, including Environment Canterbury and the
Canterbury Maps partners. Boundary information is derived under licence from LINZ Digital Cadastral
Database (Crown Copyright Reserved). Environment Canterbury and the Canterbury Maps partners do
not give and expressly disclaim any warranty as to the accuracy or completeness of the information or its
fitness for any purpose.
Information from this map may not be used for the purposes of any legal disputes. The user should
independently verify the accuracy of any information before taking any action in reliance upon it.
Map Created by Environment Canterbury on 12/11/2018 at 5:13:36 p.m.
Environment Canterbury
´Canterbury Maps
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3.1.2 Sampler set-up 
Two ISCO 3700 portable samplers, with 24 1 L bottles each, were used to collect the samples 
(Figure 3-2). Each site had two polytetrafluoroethylene (PTFE) hoses, one each for the influent 
and effluent. These were measured and cut to the nearest foot, then entered into the samplers 
and calibrated to ensure accurate and reproducible volumes of wastewater were collected. The 
hoses were replaced if they were damaged or could not be thoroughly cleaned. For each 
sampling event, an excel spreadsheet was produced, detailing the timing and volumes of the 
samples (See Appendix 1). Each sampler was set to collect 250 mL, every 30 minutes for 25.5 
hours, placing three samples per bottle (750 mL). The contents of the first bottle (first 1.5 hours 
of sampling) was disposed of as it served to flush and prime the sampler hosing. Following 
unforeseen circumstances, 125 mL samples were collected every 15 minutes at the Kaiapoi 
WWTP to reduce sample inconsistencies resulting from the large and rapid fluctuations in the 
influent volumes at the plant and to increase the likelihood of a sample being collected during 
a state of flow.  
 
All equipment that came in contact with the wastewater, including the sampler bottles, bucket, 
lids and stirrer, were soaked in Vircon for at least 24 hours following sample collection. 
Following this, they were rinsed 3 times with deionised water, then solvent-washed 3 times 
with both methanol and acetone. The sampler bottle lids were lined with aluminium foil prior 
to each sample collection and were cleaned alongside the bottles. 
Figure 3-2. ISCO 3700 portable sampler set up at Kaiapoi wastewater treatment plant and the 
sampler bottles. 
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3.1.3 Sample processing and storage 
Following sample collection, the samples were brought back to the laboratory on ice, then 
transferred and mixed in a stainless steel bucket. The composite samples were thoroughly 
homogenised, and then two aliquots of 500 mL were transferred into two solvent-washed (3x 
with each of methanol, acetonitrile and acetone) high density polypropylene (HDPE) bottles. 
The remaining wastewater (11 L) was provided to a complimentary project. The samples were 
immediately placed in the freezer (-20°C) until analysis. A sample blank of 1 L was also placed 
in the sampler for every sampling event and carried through the sampling and analytical 
methods in the same manner as the samples. The blank was also frozen in an HDPE bottle 
following the processing of the samples. 
3.1.4 Health and safety 
Prior to each field trip, a risk assessment was also completed and submitted to the Department 
Safety Officer. Due to the hazardous nature of the wastewater matrix, gloves were worn at all 
times. “Clean” jobs were done prior to “dirty” jobs, such as packing up the battery and sampler 
top unit, before putting lids onto the sampler bottles and then removing the hosing, disinfecting 
it with ethanol, and placing it in a bag for transport back to the laboratory. Gloves were replaced 
regularly and placed in a rubbish bag. Hi-visibility jackets and gumboots were worn at the 
WWTPs. The boots were also sprayed with ethanol before they were removed. All equipment 
and surfaces were regularly sprayed and wiped down with 70% ethanol. Hands were either 
washed then sanitised, or just the latter if no facilities were available. The samplers and samples 
were transported on trolleys to avoid injury, and a buddy system was used.  
3.2 Sample analysis  
3.2.1 Filtration and deconjugation  
Sample analysis was conducted in batches of 8-9: (I) Weekend and weekday effluent; (II) 
Weekend and weekday influent; and (III) Bimonthly effluent samples. First, the wastewater 
samples and field blank were removed from the freezer and defrosted in a water bath at room 
temperature. Ensuring each sample was homogenised, 200 mL was then measured, filtered and 
acidified with acetic acid to pH 5 (Figure 3-3). An additional two aliquots of 200 mL of 
wastewater was prepared and processed, to serve as the sample duplicate and spike. Following 
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this, 1.5 mL of b-glucuronidase was added, and the samples were incubated for 2 hours at 
37°C.  
3.2.2 Solid phase extraction  
Following incubation, the samples were allowed to cool. They were then spiked with 200 µl of 
a 0.1 µg/mL D4-15-F2t-IsoP surrogate solution. At the time of spiking, a comparative was also 
dispensed through adding 200 µL of a 0.1 µg/mL native-surrogate standard mix. The Strata X-
AW cartridges were pre-conditioned with 3 x 5 mL acetone, followed by 3 x 5 mL of 
methanol:acetic acid (98:2, v/v) and 5 mL ultrapure water. Each cartridge was positioned over 
the manifold, then a 5 mL aliquot of the solvent was added (Figure 3-4). Around half of the 
solvent was allowed to flow through under gravity, then the taps were closed for 2 minutes to 
allow the solvent to saturate the SPE bed. The taps were then opened and the remaining solvent 
allowed to flow through. This process was repeated for each solvent aliquot. Following the 
addition of the ultrapure water, an additional 5 mL was added to prevent the SPE bed from 
becoming exposed to air before the samples had been loaded.  
 
The samples were then run drop-wise through the cartridges under a gentle vacuum. Once the 
bottles were empty, the flow was stopped so that the bottles and tubing could be rinsed by 
passing 2 x 10 mL ultrapure water through. Following this, the cartridges were dried for 2.5 
hours. For elution, the Strata X-AW cartridges were stacked over previously-used Strata FLPR 
cartridges, which were filled with 5 g pre-baked granular sodium sulfate, and rinsed with 3 x 5 
mL acetone (Figure 3-5). The Strata X-AW cartridges were then eluted with 6 x 5 mL methanol 
into 40 mL amber glass vials. Each aliquot was allowed to sit on the SPE bed for 2 minutes 
before it was allowed to pass through under gravity. Once all of the methanol had been run 
through, the vacuum was left on for ten minutes to ensure all of the eluent had been collected. 
The samples were then prepared for silica gel chromatography (Section 3.2.2.1) or hexane 
extraction (Section 3.2.2.2).  
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Figure 3-3. Sample filtration set-up. 
 
 
Figure 3-4. Solid phase extraction set-up. 
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Figure 3-5. SPE cartridges stacked over sodium sulfate-packed cartridges for sample elution. 
 
 
3.2.2.1 Silica gel chromatography sample clean-up: Wastewater effluent 
All of the wastewater effluent samples were purified using silica gel chromatography. 
Following elution, the methanol was dried down to ~0.5 mL under a gentle stream of N2 and 
quantitatively transferred onto the silica gel columns with 2 x 250 μL methanol. Each column 
was set up in a short glass pipette with glass wool packed into the bottom. Silica gel was then 
added on to the top of the wool until the columns were ¾ full (~0.55 g), before it was then pre-
conditioned with 5 x 1 mL ethyl acetate. Each aliquot of ethyl acetate was loaded onto the silica 
and allowed to drip through under gravity before the remaining moisture was expunged using 
a pipette bulb. Once the samples had been loaded, they were eluted with 5 x 1 mL ethyl 
acetate:methanol (50:50 v/v). They were then dried down to ~0.5 mL before 200 μL (0.1 
μg/mL) of the internal standard, BPC, was added to the samples and the comparative. Then 
they were all dried down for derivatisation with MSTFA (Section 3.2.3.2).  
3.2.2.2 Hexane liquid-liquid extraction: Wastewater influent 
The hexane clean-up technique was only used for the influent samples as the method was not 
trialled until after the effluent samples had already been processed and analysed. The silica 
clean-up technique did not provide sufficient sample purification, whereas, the hexane liquid-
liquid extraction efficiently removed many of the non-polar interferences from the wastewater 
samples. Firstly, the eluted samples were dried down to 5 mL under N2, then 3 x 5 mL of 
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hexane was added. Following the addition of a hexane aliquot, each sample was thoroughly 
mixed through inversion and shaking, then left to settle for 5 minutes. Following this time 
period, the top hexane layer was carefully removed with a glass pipette and discarded. If any 
of the methanol layer was collected or disturbed during this process, the pipette contents was 
ejected back into the vial and the layers were allowed to separate again for 5 minutes, before 
the process was repeated. Once the final hexane aliquot had been added, the samples were dried 
down to ~0.5 mL under a gentle stream of N2, and quantitatively transferred into 1 mL reacti 
vials with 2 x 250 μL of methanol. These were then prepared for sample derivatisation (Section 
3.2.3.2).  
3.2.3 Sample derivatisation and GC-MS analysis  
3.2.3.1 Synthesis of the MSTFA mix 
The MSTFA was prepared by adding 95 μL of MSTFA to a reacti vial containing 3.8 mg of 
NH4I and 5.67 μL 2-mercaptoethanol. The mix, and the remaining bottle of MSTFA were 
purged with N2, before the mix was then vortexed and incubated at 65°C for around 2 hours, 
until the NH4I was fully dissolved. Following cooling, the remaining 905 μL of MSTFA was 
added to the mix and vortexed. The vial was purged with N2 following every use and stored at 
4°C for a maximum of 10 days. 
3.2.3.2 Derivatisation and sample transfer  
Once the samples had been transferred into reacti vials, they were dried under N2 at 40°C to 
~0.5 mL, and 200 μL of the BPC (0.1 μg/mL) internal standard was added. The samples were 
then dried down again before 30 μL of the MSTFA mix was added. They were then mixed and 
incubated for 45 minutes at 65°C. Once the samples had cooled for 10 minutes, the derivatised 
sample was transferred into 0.1 mL GC vial inserts and 170 μL of iso-octane was then used to 
rinse the reacti vials, before it was also transferred into the vial inserts and mixed, making the 
total volume up to 200 μL.  
3.2.3.3 GC-MS parameters and analysis  
All method development, standard and sample analysis was conducted on a GC-MS using a 
Shimadzu GC-2010 Gas Chromatograph with a Shimadzu AOC-20i autosampler coupled to a 
Shimadzu GCMSQP2010 Plus detector. A Rxi-5Sil 30 m x 0.25 mm i.d. x 0.25 μm column 
(5% diphenyl/95% dimethyl polysiloxane) from Restek (1323-127) was used to separate the 
analyte, while Shimadzu GC-MS Solution software was used to control the instrument and 
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process data. A Shimadzu 10 µl syringe was used to inject 1 µl of the sample into the injection 
port in a splitless mode, with helium as the carrier gas. The initial oven temperature was held 
at 140°C for 4 minutes, then increased at a rate of 8°C/minute to 300°C. It was then increased 
to 310°C at 20°C/minute, and held for an additional 5 minutes. The analytes were identified 
based on the parameters outlined in Table 3-2, and the concentrations were confirmed based 
upon the calibration curve run prior to each batch of samples. To ensure consistency in the 
results, multiple parameters had to be met for the results in a sample to be accepted based off 
the criteria in US EPA method 8280A.126 These were (I) The peak of the analyte occurred the 
retention time specified; (II) The ion ratios were within 20% of those specified within a 
standard; (III) Signal to noise ratio >2.5; (IV) Had a concentration greater than the detection 
limit (Section 2.3.4); and (V) Surrogate matched all of these criteria. Results were marked not 
detected (ND) if the values for (II), (III) and (III) were significantly different from those 
specified and if (I) was not met. Results which met (I), (II), and (III) but not (V) and/or (IV), 
were marked lower than the detection limit (LOD). 
 








15-F2t-IsoP 395 481, 537 21.815 
D4-15-F2t-IsoP 391 485, 541 21.840 
BPC 385 386, 400 17.615 
 
3.2.3.4 Method detection limit 
The method detection limit (MDL) was determined through the signal-to-noise approach,127 
based on the mean lowest concentrations which resulted in a S/N >2.5. This value was also 
checked through ensuring that sharp, clear and accurately quantifiable peaks could be 
identified. Due to the complexity of the matrix and the low recoveries however, a conservative 
approach to the MDL was also selected to ensure confidence in the results, resulting in a MDL 
of 8.0 ng/L. Although this number is higher than the value calculated based solely on the S/N 
approach, it ensured more confidence in the final results. It also meant that some results which 
did meet the other criteria, and produced accurately identifiable peaks, could not be included 
in the final results as their concentration values were lower than the MDL (1.5-8.0 ng/L).  
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3.2.4 Recovery and recovery correction calculations 
Sample recoveries were calculated based on the surrogate concentration in extracted samples, 
and the concentration of the surrogate in the comparative standard (Equation 3-1): 
R% =  
Cs 
x 100 Equation (3-1) 
CCp 
R% = Recovery  
Cs = Detected concentration of surrogate  
CCp = Detected concentration of the surrogate in the comparative 
 
Due to the low sample recoveries, recovery corrections were calculated to provide provisional 
data:  
RC =  
CA 
x100 Equation (3-2) 
R% 
CA = Detected concentration of analyte  
Rc = Recovery corrected concentration  
3.2.5 Calibration curve  
A ten-point calibration (1, 2.5, 5, 10, 25, 50, 100, 250, 500 1000 ng/mL) was run with every 
batch of samples (Figure 3-6). It was prepared from the appropriate volumes of native and 
surrogate mixes. The standards were added to reacti vials, alongside 200 μL of 0.1 μg/mL BPC, 
and dried down under a gentle stream of N2. They were then derivatised with MSTFA as 
described in Section 2.3.3. They were then transferred into GC vial inserts and analysed.  
 
Figure 3-6. An example calibration curve. 
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3.2.6 Quality assurance and quality control 
Glassware cleaning 
All glassware was washed three times each with HPLC grade methanol, acetonitrile and then 
acetone. If the glassware was difficult to clean, dichloromethane was also used following the 
methanol. Any equipment which came in contact with the samples prior to extraction was also 
cleaned with Vircon, and rinsed with de-ionised water (3 x) prior to the solvent washing. The 
SPE equipment, including the Teflon transfer lines and end caps, were cleaned by passing 
methanol, acetonitrile and acetone through the tubing. The outside of the transfer line was also 
cleaned with each solvent.  
Analytical QA/QC 
Each sample batch consisted of 8-9 samples, a field blank, sample duplicate, sample spike, 
cartridge blank and a cartridge spike. Each of which was processed and extracted 
simultaneously to the samples. Prior to extraction, 200 μL of 0.1 ppm D4-15-F2t-IsoP surrogate 
was spiked into every solution, including the samples, field blanks and spikes. The native (200 
μL of 0.1 ppm 15-F2t-IsoP) was also added to the sample and cartridge spikes, and the 
comparative. Spike recoveries were calculated based on the concentration in the sample spike, 
divided by the concentration in the comparative. Any analyte detected in the cartridge blank or 
field blank was used to correct for analyte in the results.  
Instrumental QA/QC 
Several quality control practices were employed to maintain optimal instrumental analysis 
conditions. Prior to each batch of sample analysis and calibration standards, the rinse solvents 
(consisting of iso-octane, toluene and dichloromethane) and septas were changed. The injection 
needle was also thoroughly cleaned with a dichloromethane:methanol (95:5, v/v) mix, to ensure 
there were no residual crystals present which can form as a result of the derivatisation agent. 
Before and following each sample injection, the syringe was programmed to rinse three times 
in each of the rinse solvents. Duplicates were analysed every ten samples to ensure that there 
was no reduction in signal. At the beginning of each batch, an iso-octane blank was run. While 
following a sample sequence, three iso-octane blanks were run to flush any volatiles from the 
system which may have accumulated over the course of the batch. The results of these blanks 
were checked after the run to ensure that the background noise was at an acceptable level, so 
as not to cause any interferences. An iso-octane blank was also run half-way through a sample 
sequence to flush the instrument. Whenever the glass liner was changed, multiple standards 
and environmental samples were injected and run to ensure that the active sites within the 
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injection port were stabilised. Tuning files were also run to ensure that the instrument was 
operating under optimal parameters. Following an instrument tune, a calibration curve was 





Survey of Canterbury wastewater treatment plants 
4.1 Characterisation of the wastewater treatment plants 
A series of WWTPs were surveyed to determine the concentrations of 15-F2t-IsoPs present in 
their wastewater (Section 3.1), following the design and validation of an analytical method to 
enable their detection (Chapter 2). This survey was conducted to investigate whether WWTPs 
could represent a source of IsoPs to the environment where they may act as potential emerging 
contaminants (ECs).18, 54 The WWTPs sampled in this research were selected to reflect varying 
treatment processes, flow rates, size and degree of urbanisation of the catchment populations, 
and volumes of groundwater infiltration (Table 4-1). Each of these factors has the potential to 
determine the concentrations of contaminants,128, 129 including IsoPs, present in the influent, as 
well as their rate of removal. The flow and population data presented in Table 4-1 are average 
values, which are unlikely to reflect the daily or seasonal fluctuations,130 as multiple factors 
can cause variations in local population statistics and wastewater flows. In Canterbury 
specifically, a series of earthquakes in the region damaged the sewage pipes, increasing 
groundwater infiltration into the wastewater network.131 Following high rainfall events, 
increased wastewater influent dilution can occur, especially in the Bromley and Lyttelton 
WWTPs.131 Sampling during high rainfall events was avoided when possible, however higher-
than-average flows can remain for the following days. Daily commute between different areas 
can also alter human-waste inputs which may consequently alter the volume of human 
biological waste entering the plants, although the influence of this was expected to be 
minimal.132 
4.2 Isoprostane concentrations detected in the survey of Canterbury 
wastewater treatment plants 
The provisional survey results are presented in batches of sample extraction and analysis. This 
is to account for: (I) the differences in sample purification methods for the effluent (silica gel 
chromatography, see Section 3.2.2.1) (Table 4-2 and 4-3) and influent samples (hexane liquid-
liquid chromatograph, see Section 3.2.2.2) (Table 4-4); and (II) the weekend versus weekday 
(Table 4-2),  and  bimonthly  (Table 4-3)  temporal  characterisation  of  IsoP  concentrations  in
wastewater effluent. 
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Table 4-1. Characterisation of the WWTPs surveyed in this research. Note: Population, volume treated and daily flow data are approximate values.133 
 Bromley Kaiapoi Lyttelton Governors Bay 
Population 368,000 10,700 3137.2 646.8 
Volume 
treated (m3/yr) 
68,237,480 1,621,651 348,521 73,444 
Daily flow 
(m3/d) 





- Screen to trap larger material and 
grit 
- Sedimentation tanks to remove 
heavy organic matter (which is 
then digested) 
- The liquid waste is then pumped 
into the top of trickling filters, 
allowing the bacteria to consume 
the nutrients in the wastewater. 
- Aeration tanks 
- Clarifiers (to allow bacteria slime 
to settle out of the liquid) 
- Oxidation ponds  
- Ocean outfall134 
- Screening 
- Aeration basin to reduce organic 
load 
- Oxidation pond 
- Infiltration wetland 
- Rangiora effluent then enters the 
infiltration wetland, mixing with 
the Kaiapoi effluent, before it all 
passes through a smaller, planted 
wetland 
- Ocean outfall 
- A UV disinfection system is also 
used when bacteria levels are 
high.135 
- Screening 
- Extended aeration 
- UV disinfection 
- Sludge dewatering 
- Ocean outfall136 
- Screening to remove 
large matter 
- Extended aeration 
- UV disinfection 




30% groundwater infiltration 
10% industrial waste 
60% domestic waste 
Some infiltration 
Considered mostly domestic waste 
>90% domestic waste 
Some groundwater 
infiltration 
>90% domestic waste 
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Table 4-2. Batch 1 results for the analysis of weekend and weekday effluent samples. The table displays the concentrations of the analyte (15-F2t-IsoP), the 
deuterated surrogate (D4-15-F2t-IsoP), and the analytes recovery corrected concentration (Rc) (ng/L). 
Analyte Blank 
Lyttelton Bromley Kaiapoi Governor’s Bay 
LWE-E LWD-E LWE-ED* BWE-E BWD-E KWE-E KWD-E GBWE-E GBWD-E 
15-F2t-IsoP ND LOD 8.2 LOD ND ND ND LOD ND LOD 
D4-15-F2t-IsoP 36.1 44.0 52.6 68.3 35.7 LOD LOD 82.9 LOD 54.4 
R% D4-15-F2t-
IsoP 28.6 33.3 41.7 54.1 28.3 LOD LOD 65.8 LOD 43.1 
RC 15-F2t-IsoP ND LOD 19.6 LOD ND ND ND LOD ND LOD 
*D = Duplicate  
R% = Recovery; L = Lyttelton; B = Bromley; K = Kaiapoi; GB = Governor’s Bay; WE = Weekend; WD = Weekday; and E = Effluent samples.  
 
Table 4-3. Batch 2 results for the analysis of the bimonthly (August, October and December) effluent samples. The table displays the concentration of the 
analyte (15-F2t-IsoP), deuterated surrogate (D4-15-F2t-IsoP), and the analytes recovery corrected concentration (Rc) (ng/L). 
Analyte Blank 
Lyttelton Bromley Kaiapoi 
LE-A LE-O LE-D LE-DD* BE-A BE-O BE-D KE-A KE-O KE-D 
15-F2t-IsoP ND LOD 10.3 10.7 17.3 15.6 9.2 LOD 24.5 ND 9.17 
D4-15-F2t-IsoP 64.5 18.40 39.5 41.8 35.7 56.6 29.5 LOD 85.4 LOD 23.6 
R% D4-15-F2t-
IsoP 55.9 LOD 34.3 36.3 30.9 49.1 25.6 LOD 74.1 LOD 20.4 
RC 15-F2t-IsoP ND 7.5 29.9 29.6 55.9 31.7 35.9 LOD 33.1 ND 44.9 
D* = Duplicate  
R% = Recovery; L = Lyttelton; B = Bromley; K = Kaiapoi; GB = Governor’s Bay; E = Effluent; A = August; O = October; and D = December samples.  
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Table 4-4. Batch 3 results for the analysis of the weekend and weekday influent samples. The table displays the concentrations of the analyte (15-F2t-IsoP), 
deuterated surrogate (D4-15-F2t-IsoP), and the recovery corrected concentration of the analyte (Rc) (ng/L). 
Analyte Blank 
Lyttelton Bromley Kaiapoi** Governor’s Bay 
LWE-I LWD-I BWE-I BWD-I BWD-ID* KWD-I GBWE-I GBWD-I 
15-F2t-IsoP ND 19.9 LOD 12.6 ND ND 22.9 LOD LOD 
D4-15-F2t-IsoP 76.1 76.9 LOD 20.2 LOD LOD 67.6 LOD LOD 
R% D4-15-F2t-
IsoP 
59.7 60.3 LOD 15.8 LOD LOD 53.0 LOD LOD 
RC 15-F2t-IsoP ND 33.2 LOD 79.9 ND ND 43.2 LOD LOD 
*D = Duplicate 
**Due to a sampler issues, Kaiapoi weekend influent was not analysed 
R% = Recovery; L = Lyttelton; B = Bromley; K = Kaiapoi; GB = Governor’s Bay; WE = Weekend; WD = Weekday; and I = Influent samples
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Due to the low recoveries of the methods (Table 2-8), the tables display both the recovery-
corrected (Rc) and non-recovery corrected concentration data. The inclusion of the recovery- 
corrected data was important to more accurately establish the concentrations of IsoPs which 
may be present in wastewater, particularly for the effluent samples purified through the silica 
gel, which had the lowest recoveries (mean 46%) and clean-up efficiency. The results were 
only deemed acceptable if they met the specified criteria outlined in Section 3.2.3.3. 
Unfortunately, many results were marked as LOD, due to the deuterated surrogate not meeting 
the specified criteria, even though the analyte did. Further sample clean-up trials, as well as 
running all of the effluent samples through the hexane purification technique, may improve the 
results in future.  
 
In the survey, 15-F2t-IsoPs were detected at three of the four WWTPs, in both the influent and 
the effluent. No IsoPs were detected at the smallest WWTP, Governor’s Bay, which may be 
due to a combination of the low population and the need for more sensitive analytical methods. 
Across the plants, the recovery-corrected concentrations range from ND-79.9 ng/L and ND-
55.9 ng/L in the influent and effluent, respectively. Although 15-F2t-IsoPs have been detected 
in the survey of the WWTPs, due to the provisional nature of the data, further investigation is 
required. In future, additional method development, and the analysis of a greater number of 
samples is necessary to more accurately determine any definitive trends in IsoP concentrations.  
4.2.1 Trends between plants 
Given that IsoPs are endogenously produced compounds, it was hypothesised that WWTPs 
with higher mammalian waste inputs (i.e. domestic or agricultural waste), would also have 
greater IsoP concentrations present in their wastewater. The WWTPs surveyed in this study 
primarily process domestic waste, with only Bromley processing a significant proportion of 
other (industrial) waste (Table 4-1). At this stage, no trends related to the proportion of 
mammalian inputs can be identified. Additionally, no seasonal associations or trends were 
identified based on the bimonthly sample results within each WWTP (Table 4-2). However, 
more sensitive analytical methods may be required for future certainty. 
 
The preliminary results in Table 4-4 indicate that when detected, there are greater (recovery-
corrected) concentrations of 15-F2t-IsoP in the influent of the larger WWTPs such as Bromley 
and Kaiapoi (76.9 and 43.2 ng/L), compared to Lyttelton and Governor’s Bay (33.2 ng/L and 
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LOD) (Table 4-4). However, a greater range of data is required to determine the significance 
and reproducibility of these values, as with improved data collection, a more robust assessment 
of IsoPs as ECs can be made.   
4.2.2 Removal efficiencies of isoprostanes from wastewater  
Higher concentrations of 15-F2t-IsoPs were detected in the influent (ND-79.9, mean 17.4 ng/L) 
compared to the effluent (N.D-55.9, mean 13.2 ng/L), which indicates that WWTP processing 
reduces the concentrations of IsoPs present in wastewater (Table 4-5). However, although the 
retention times of the of WWTPs are 4-48 hours (Table 3-1), 15-F2t-IsoPs were still detected 
in the effluent, which infers that IsoPs are stable in wastewater for greater than 24 hours. This 
result is consistent with previous stability studies, and suggests that IsoPs may also remain 
stable in environmental matrices.106 It is also important to note that the concentrations detected 
in the influent and the effluent are not fully representative of what may actually be present in 
wastewater, as further method development is required to improve recoveries, remove 
interfering substances and lower the detection limit, which would improve the quantification 
of the IsoPs.  
 
Table 4-5. Comparison between the influent and effluent, weekend and weekday, 15-F2t-IsoP 
concentrations (raw and recovery-corrected concentrations, ng/L). 
 
R% = Recovery; L = Lyttelton; B = Bromley; K = Kaiapoi; GB = Governor’s Bay; WE = Weekend; 







Lyttelton Bromley Kaiapoi G. Bay 
LWE LWD BWE BWD KWE KWD GBWE GBWD 
Influent IsoPs 19.99 LOD 12.63 NQ N/A 22.9 LOD LOD 
Effluent IsoPs LOD 8.2 ND ND ND LOD ND LOD 
RC Influent 
IsoPs 33.2 LOD 79.9 NQ N/A 43.2 LOD LOD 
RC Effluent 
IsoPs LOD 19.6 ND ND ND LOD ND LOD 
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An additional factor which may be determining the removal rates of IsoPs from wastewater 
may be their physical sequestration onto solid-phase organic matter and sludge.137 The phase 
partitioning of IsoPs is not currently understood and additional research is required to 
determine their partition coefficient (Kd) which may be used to derive these phase 
interactions.137 Any possible phase partitioning may be dependent upon whether the IsoPs are 
in their glucuronide-conjugate forms, as conjugation commonly increases the polarity and 
hydrophilicity of molecules which can decrease their partitioning to the solid-phase.138, 139 
Alongside removing IsoPs from the liquid phase in the wastewater, sorption could also be 
decreasing the concentrations of IsoPs available for detection using the described analytical 
method. Additionally, these sorption processes and interactions may also affect the behaviour 
of IsoPs following their environmental discharge, and will consequently need to be further 
investigated. 
4.2.1 Weekend versus weekday isoprostane concentrations 
Elevated IsoP concentrations (including 15-F2t-IsoP) are detected in the blood and urine in 
response to drug and alcohol consumption.140, 141 As a result, it was anticipated that greater 15-
F2t-IsoP concentrations may be present in the weekend compared to the weekday samples, due 
to an increase in recreational substance abuse.142-144 Based on these preliminary results, there 
is no discernible link between 15-F2t-IsoP concentrations and the period of the week (Table 4-
5). For example, while there appears to be a temporal trend at the Lyttelton WWTP based on 
the greater IsoP concentrations detected in the weekend (RC, 33.1 ng/L) compared to the 
weekday (LOD) influent samples, the effluent concentrations contradict this result, with higher 
concentrations detected in the weekday (RC, 19.6 ng/L) compared to the weekend (LOD) 
effluent samples (Table 4-5). As a result, more reliable data, collected at a larger scale may be 
required to determine if there is a temporal difference in IsoP concentrations. Ryu et al 
(2016)109 were also unable to identify a temporal trend in IsoP concentrations in European 
WWTP wastewater. The absence of any observed differences between weekday and weekend 
IsoP concentrations could be due to the difficulty of collecting representative wastewater 
samples throughout the treatment plants. In WWTPs that serve larger urban areas such as 
Bromley, untreated wastewater can pass through multiple pumping stations prior to reaching 
the WWTP.145 As a result, it can take multiple days for the wastewater to enter the WWTP, 
and the influent being sampled may not reflect any temporal changes.  
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4.3 Isoprostane loading and comparison to biological matrices 
Greater 15-F2t-IsoP loads were observed in wastewater influent by Ryu et al (2015 and 2016)106, 
109 and Santos et al (2016)108 in association with increased urbanisation. A population 
normalisation equation, adapted from Ryu et al (2015 and 2016)106, 109 was used to determine 
the predicted IsoP loads in Canterbury influent based on the recovery corrected concentrations 
(Equation 4-1, Table 4-6).  
IsoPs load per day per 1000 people 
(mg/d/1000 people) =  ( ((CIsoP/1000) mg/m3 x Daily flow m3/d) ) x 1000 
Population 
                Equation (4-1) 
 
CIsoP = Recovery-corrected concentration of 15-F2t-IsoP in the influent 
 
The IsoP loads calculated in Table 4-6 represent approximate values due to the provisional 
nature of the results. The normalised values indicate that the more urbanised Bromley WWTP 
(which serves the majority of Christchurch City), has the greatest IsoP load (40.6 mg/d/1000 
people) in comparison to the other plants (Table 4-6), which follows a similar trend to those of 
Ryu et al (2016).109 Despite this, the values found in this research are an order of magnitude 
greater than those calculated by Ryu et al (2016).109 This may be the result of using the 
recovery-corrected concentrations, and may be amended through conducting a reassessment 
using improved analytical methods. 
 
One explanation for the link between urbanisation and the IsoP loads identified in this study 
(as and in European cities), may be that urbanised communities have an increased ratio of 
individuals suffering from elevated oxidative stress levels. For example, oxidative stress and 
mental impairment are elevated in urban versus rural aging communities.146 Alongside the 
ever-increasing size of elderly populations, age contributes to elevated IsoP concentrations, 
both directly through increasing oxidative stress, and indirectly due to the link between age 
and an increased incidence of disease, such as Alzheimer’s and cardiovascular disease 
(CVD).147, 148 149 It is also common for urbanised areas to have a number of medical facilities 
(e.g. hospitals and procedural clinics), that are representative of localised areas of chronically 
or acutely unhealthy individuals. For example, the Bromley WWTP serves at least three 
hospitals and multiple medical facilities, whereas the other plants only serve smaller healthcare 
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providers. Consequently, it is expected that medical facilities could be significant contributors 
to IsoP concentrations in wastewater, as many ailments or diseases which warrant admission 
to hospitals are also linked to oxidative stress.71 In addition to this, urbanisation is linked to 
higher rates and risks of disease incidence, with air pollution especially, believed to contribute 
to oxidative stress and respiratory diseases such as asthma.150, 151 Each of these factors may at 
least partially account for the relationship between IsoPs and urbanisation. Moreover, the 
discharge of these compounds into urban environments is likely to have adverse physiological 
impacts on the biota living in these areas. Especially, given their pre-existing elevated states of 
oxidative stress, effectuated in response to increased exposure to anthropogenic pollutants in 
these urban habitats.152 
 
Table 4-6. A comparison between daily isoprostane loads per 1000 individuals, based on Canterbury 
survey data and literature values from Ryu et al (2016).109 
*Using recovery corrected concentrations 
L = Lyttelton; B = Bromley; K = Kaiapoi; GB = Governor’s Bay; WE = Weekend; and WD = Weekday 
Wastewater 
sample ID Population 
Wastewater 
flow (m3/d) 
Daily load per capita 
(mg/d/1000 people) 
Canterbury Survey*   
BWD-I 368,000 186,952 40.6 
KWD-I 10,700 4419 17.8 
LWE-I 3137.2 828 8.8 
Literature values109   
Bristol 886,650 202,224.3 2.6 
Brussels 953,987 265,681.8 2.8 
Castellon 180,690 39993.5 2.6 
Copenhagen 531,000 143,287.0 4.9 
Hamar 55,000 50,695.1 5.5 
Milan 1,100,000 493,085.71 5.0 
Oslo 580,639 274,588.6 10.0 
Stavanger 240,000 229,706.6 8.0 
Tromsø 20,000 18,220.8 7.7 
Utrecht 300,000 46,425.0 2.5 
Zurich 410,000 190,278.0 7.8 
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4.3.1 Wastewater versus biological isoprostane concentration comparisons, and 
their relevance as emerging contaminants 
The IsoP loads determined in this study (8.8-40.6 mg/d/1000 individuals), and by Ryu et al 
(2016)109 are significantly larger than those previously calculated for urinary IsoP loads (0.1-5 
mg/day/1000 individuals).109 This latter value was hypothesised based on the daily urinary 
excretion data, which is considered to be between 100-5000 ng/day/person, depending on the 
isomer, with most in the range of 1000-2000 ng/day/person.17, 153 The discrepancies between 
these per capita loads, may be due to the fact that the hypothesised range is based upon IsoP 
concentrations detected in the urine of healthy individuals, and does not take into account that 
a proportion of the population may be under elevated levels of oxidative stress, which could be 
skewing the data collected in this study and Ryu et al (2016)109 to higher IsoP concentrations.  
 
The recovery-corrected concentrations of 15-F2t-IsoP detected in wastewater influent (ND-
79.96 ng/L) and effluent (ND-55.96 ng/L), are lower than the concentrations excreted in the 
urine of healthy individuals 100-1200 ng/L.154, 155 This was to be expected, due to the 
breakdown and dilution of these molecules in wastewater. Despite this, these concentrations 
are still within the range of those detected in blood (0.035-45.1 ng/L),17, 71 suggesting that they 
may be biologically-relevant concentrations, potentially capable of interacting with 
biomolecules within exposed organisms.  
 
Based on the presence of 15-F2t-IsoPs in wastewater effluent, there is the potential for these 
molecules to be released into the wider environment. Although increased dilution of these 
concentrations is likely to occur, given that 15-F2t-IsoPs have been found to remain stable in 
wastewater,106 they may also remain stable in environmental matrices long enough to result in 
pseudo-persistence where, like other known ECs (e.g. endocrine disruptors and PPCPs), they 
may also represent ecotoxicological risks.4, 156 Previous assessments of other ECs in 
wastewater and surface water, have demonstrated that that even when only relatively low 
concentrations of contaminants are detected in wastewater effluent, they can still be discharged 
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Table 4-7. The concentrations of other known emerging contaminants in wastewater effluent and 













ND = Not detected 
 
These preliminary results provide a representation of IsoP concentrations in Canterbury 
wastewaters. Considerable work was conducted to improve the extraction and detection 
methods of IsoPs in wastewater, to contribute to this area of research. As such, these 
provisional results provide a platform from which further investigation may conducted
Contaminant Effluent (ng/L) Surface water (ng/L) 
17a-estradiol157, 158 0.1-5.0 0.1-3.0 
17b-estradiol157, 158 0.4-12.0 0.3-2.8 
Androstenedione158 4.5-12.0 3-9.0 
Androsterone158 N.D-4.3 ND 
Bisphenyl A159, 160, 161 35.0-86.0 <6.0-34.0 
Butylparaben159, 160  <1.0 <0.3-6.0 
Estrone157, 158 0.1-47.0 0.1-3.5 
Methyl paraben159, 160 <3-50 <0.3-68 
Testosterone158 0.7-1.2 0.1-0.5 
Triclosan159, 160, 161 25.0-200.0 5.0-48.0 
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Chapter 5 
Conclusions, limitations and recommendations  
5.1 Summary of research and findings 
5.1.1  Summary of research 
The objectives of this thesis were to; (I) develop a GC-MS analytical method to measure IsoPs 
in wastewater; and (II) survey the concentrations of 15-F2t-IsoP in the influent and effluent 
collected from WWTPs around the Canterbury region, to determine if wastewater may 
represent a source of IsoPs to the environment. This is the first known study to analyse IsoPs 
in wastewater from an EC perspective, and although more work is required to refine the 
extraction and detection techniques, significant steps have been made utilising and adapting 
the range of methods already available in the literature.  
 
Most importantly, to enable the analysis of IsoPs in wastewater, novel extraction and 
derivatisation techniques were established. Initially, DIMETRIS, a recently developed 
derivatisation agent was trialled (Section 2.3). Extensive efforts to identify the ions 
representative of the IsoP were unsuccessful. As this derivatisation agent had previously only 
been used for the esterification of aromatic ring-containing compounds, the lack of success 
may have been a result of 15-F2t-IsoP and DIMETRIS being incompatible.117, 118 Next, a 
combination of BSTFA with PFB-Br, which are commonly used for the analysis of IsoPs,94, 
102, 120 were trialled and were also unsuccessful (Section 2.3.2). The reasons behind this were 
unable to be discerned, and future investigation is required. Finally, derivatisation with 
MSTFA was developed and resulted in the reliable detection of 15-F2t-IsoP.  
 
Subsequently, a method was developed for the extraction of IsoPs from wastewater with a b-
glucuronidase deconjugation pre-treatment, followed by SPE on Strata X-AW cartridges. Both 
silica gel chromatography and hexane liquid-liquid extraction were validated for sample 
purification, although the latter was more efficient with improved analyte recovery (Section 
2.4). These methods were then combined to allow for the analysis of IsoPs in wastewater 
samples. The wastewater samples were collected from four WWTPs around the Canterbury 
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Region. Both weekend and weekday, influent and effluent samples were collected to determine 
if there were any differences in the concentrations of IsoP depending on the period of the week. 
Finally, effluent samples were collected bimonthly over 6 months, to investigate the presence 
of any seasonal trends.  
5.1.2  Summary of findings: Isoprostanes as potential emerging contaminants? 
Isoprostanes have been postulated to act as potential contaminants by initiating a cycle of 
oxidative stress throughout ecosystems (Section 1.5).18 The results of this research indicate that 
IsoPs are present in the wastewater of Canterbury WWTPs, and that these compounds are not 
sufficiently removed during the treatment process (Section 4.2.2). Consequently, suggesting 
that the discharge of effluent may represent a source of these bioactive compounds to the 
environment, where they may trigger a cycle of oxidative stress, amplifying it throughout the 
receiving ecosystems.54 Although no temporal trends could be observed, additional research is 
required to refine a more sensitive analytical technique and achieve improved quantification. 
Further investigation is also required to ascertain their roles as ECs, as no definitive conclusion 
can be reached until toxicology research and fate studies of these molecules in surface waters 
have been conducted.12, 54  
 
These preliminary results provide a representation of the IsoP concentrations present in 
wastewater, and an indication of those which may be released into the wider environment. 
Based solely on these concentrations, and without a detailed understanding of their 
environmental fate, IsoPs may be ECs of concern, especially considering that their loads in 
wastewater are linked to the degree of urbanisation of the surrounding population. In many 
cities, wastewater is discharged into nearby freshwater ecosystems, such as rivers and 
streams.162 Due to the urban nature of these waterways, even without wastewater inputs, they 
are often in already degraded states. This state, termed the Urban Stream Syndrome (USS),163 
comprises various symptoms including altered hydrology, poor species diversity, high 
sediment loads, and elevated contaminant and nutrient concentrations that adversely affect the 
overall quality and sustainability of urban freshwater ecosytems.163 The release of additional 
contaminants through wastewater could have untold detrimental effects on these already 
degraded ecosystems. If IsoPs do prove to be contaminants of concern, they may be placing 
additional pressure and stress on the organisms within these ecosystems. Especially, if they are 
capable inducing of oxidative stress and other pathological processes.  
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Endogenous compounds excreted by humans and other mammalian species are likely to 
become greater concerns as a consequence of rising populations. Rising human and other 
mammalian (e.g. agricultural livestock) population densities may mean that excreted 
endogenous compounds will continue to become a growing concern. Increasing population 
density will place greater strains on wastewater networks, while also augmenting the volume 
of biological waste which will be released into the environment.164 The accidental release of 
untreated wastewater through wastewater overflows may also result in the discharge of 
wastewater directly into waterways. Resulting in the highly concentrated release of 
contaminants, potentially including IsoPs, and triggering a range of biological impacts which 
may alter the natural physiological functions of the aquatic biota present in these receiving 
ecosystems.54 
5.2 Research limitations and recommendations 
The two primary limitations of this study were the low recoveries of the extraction method and 
the inefficient sample clean-up. Further method development is required to attain improved 
extraction and purification procedures, which may allow for lower detection limits and better 
quantification of the IsoPs in wastewater. Alternative clean-up procedures may include trialling 
different solvents (e.g. alternative mixtures of solvents or those with different polarities) 
through silica gel chromatography, alumina clean-up and gel permeation chromatography 
(GPC). These clean-up procedures are commonly used for the purification of environmental 
matrices for the analysis of other ECs, and may also be applicable for IsoP analysis.165, 166 As 
a subset of size exclusion chromatography, GPC in particular, may be a useful technique to 
separate the target analyte from the interfering substances in the matrix.167 Briefly, the whole 
sample is loaded and eluted from the GPC column. The larger molecules, including fats (which 
are considered to be the primary interferences for IsoP detection in this method), are eluted in 
an earlier fraction which is then discarded, and only the fraction containing the analyte is 
collected, as a result hopefully improving IsoP quantification.  
 
Numerous SPE procedures are also described in literature, most of which were unable to be 
trialled due to the time constraints of this project. Altering the pre-conditioning solvents, 
adding wash steps, changing the elution solvent and testing different SPE cartridges are all 
alternatives which may improve the extraction of the IsoPs from the matrix and the 
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recoveries.168 Introducing a hexane wash step to the current extraction procedure may also 
improve the removal of interferences from the sample (in particular, the non-polar fats and 
lipids).169 Immunoaffinity chromatography is another effective method for sample preparation 
and purification,104 which based on the methods of Ryu et al (2015),106 provides efficient clean-
up of wastewater for IsoP analysis, and may be trialled prior to GC-MS. 
 
Gas chromatography coupled to mass spectrometry was selected for the purpose of this 
research as it was the most sensitive, low cost method available. However, LC-MS may be 
used as an alternative analytical technique as it has the potential to improve the quantification 
of IsoPs, while enabling simpler sample preparation through eliminating the need for the 
derivatisation reaction, which can otherwise decrease analyte recoveries.170 However, an issue 
with LC-MS is its low sensitivity in comparison to GC-MS.96 This may mean that tandem mass 
spectrometry will be required to achieve lower method detection and quantification limits.170 
 
An additional limitation is the small-scale nature of the survey of WWTPs. Implementing a 
larger sampling program would enable a greater number of samples to be collected on a 
temporal (i.e. more samples per plant over time) and spatial (i.e. more WWTPs) scale. This 
would be constructive to determine how different circumstances (i.e. the population, 
urbanisation, treatment processes and flow rates) affect the concentrations present. This may 
help provide more reliable and robust data, from which any trends in IsoP concentrations may 
be more accurately determined. The sampling of WWTPs with lower groundwater influences 
may also be beneficial as it will ensure that the primary contributing factors influencing IsoP 
concentrations are the population, the proportion of domestic, agricultural and industrial waste, 
and the degree of urbanisation of the surrounding area.  
 
Wastewater land application and the use of biosolids as soil amendments represent alternative 
environmental fate pathways for many contaminants.171 Further consideration of the behaviour 
of IsoPs may be required due to the increasing incidence of these wastewater disposal 
techniques. Additionally, the sampling of dairy shed effluents may be of interest, to determine 
if agricultural activities may also represent a source of these compounds to the environment, 
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which, combined with the high nutrient and pathogen loads,172, 173 may be placing additional 
pressures on ecosystems, especially the sensitive freshwater streams of New Zealand. 
Alongside the development of a more robust analytical method, the one developed in this thesis 
may still be applicable for the analysis of other, less complicated environmental matrices. The 
complexity of the wastewater matrix was one of the primary issues limiting IsoP quantification 
in this study. As a result, the method may be more successful for the analysis of surface water 
(e.g. fresh and saltwater), in preliminary investigations regarding the presence of IsoP 
molecules in the wider environment.  
5.3 Final conclusions 
The discharge of wastewater effluent from WWTPs represents a continuous source of 
contaminants to the environment. Such discharges may serve as a pathway for the entry of 
biologically-active IsoP molecules to aquatic environments. As the deleterious mechanisms of 
oxidative stress are conserved between species, the exposure of aquatic organisms to IsoPs may 
result in the initiation of a cycle of oxidative stress. This may subsequently translate to the 
spread of oxidative stress throughout the localised environment, much like a contagious 
disease, and putatively lead to the excretion of additional IsoPs and the continuation of the 
cycle.  
 
This body of work successfully contributes to the current research regarding the concentrations 
of IsoPs in WWTPs and their potential roles as ECs. To further this area of research, more 
work is required to refine existing extraction and detection methods, in order to reliably assess 
the role of IsoPs as contemporary ECs. Comprehensive surveys on their environmental 
concentrations, alongside a series of ecotoxicological and biological assays are also required. 
Simply establishing that IsoPs may be entering aquatic environments does not constitute as 
tangible proof that they will pose a threat, and this environmental fate data is necessary to begin 
to evaluate their risks as ECs. The discharge of wastewater into sensitive environments is a 
burgeoning issue worldwide. Further research into the plethora of other bioactive compounds 
present in wastewater is imperative to ensure that effective risk management can occur, and to 







“An understanding of the natural world and what's in it is a source 
of not only great curiosity but great fulfilment.” 
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Appendix 1: A sampling timetable example  


















8:00 1 250 250 13:00 1 250 250 
8:30 1 500 500 13:30 1 500 500 
9:00 1 750 750 14:00 1 750 750 
9:30 2 250 250 14:30 2 250 250 
10:00 2 500 500 15:00 2 500 500 
10:30 2 750 750 15:30 2 750 750 
11:00 3 250 1000 16:00 3 250 1000 
11:30 3 500 1250 16:30 3 500 1250 
12:00 3 750 1500 17:00 3 750 1500 
12:30 4 250 1750 17:30 4 250 1750 
13:00 4 500 2000 18:00 4 500 2000 
13:30 4 750 2250 18:30 4 750 2250 
14:00 5 250 2500 19:00 5 250 2500 
14:30 5 500 2750 19:30 5 500 2750 
15:00 5 750 3000 20:00 5 750 3000 
15:30 6 250 3250 20:30 6 250 3250 
16:00 6 500 3500 21:00 6 500 3500 
16:30 6 750 3750 21:30 6 750 3750 
17:00 7 250 4000 22:00 7 250 4000 
17:30 7 500 4250 22:30 7 500 4250 
18:00 7 750 4500 23:00 7 750 4500 











19:00 8 500 5000 0:00 8 500 5000 
19:30 8 750 5250 0:30 8 750 5250 
20:00 9 250 5500 1:00 9 250 5500 
20:30 9 500 5750 1:30 9 500 5750 
21:00 9 750 6000 2:00 9 750 6000 
21:30 10 250 6250 2:30 10 250 6250 
22:00 10 500 6500 3:00 10 500 6500 
22:30 10 750 6750 3:30 10 750 6750 
23:00 11 250 7000 4:00 11 250 7000 
23:30 11 500 7250 4:30 11 500 7250 
0:00 11 750 7500 5:00 11 750 7500 
0:30 12 250 7750 5:30 12 250 7750 
1:00 12 500 8000 6:00 12 500 8000 
1:30 12 750 8250 6:30 12 750 8250 
2:00 13 250 8500 7:00 13 250 8500 
2:30 13 500 8750 7:30  13 500 8750 
3:00 13 750 9000 8:00 13 750 9000 
3:30 14 250 9250 8:30 14 250 9250 
4:00 14 500 9500 9:00 14 500 9500 
4:30 14 750 9750 9:30 14 750 9750 
5:00 15 250 10000 10:00 15 250 10000 
5:30 15 500 10250 10:30 15 500 10250 
6:00 15 750 10500 11:00 15 750 10500 
6:30 16 250 10750 11:30 16 250 10750 
7:00 16 500 11000 12:00 16 500 11000 
7:30  16 750 11250 12:30 16 750 11250 
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Appendix 2: Quality control and assurance data  
Analytical quality control data for each batch (ng/L). 






















15-F2t-IsoP ND 49.1 52.9 ND ND 27.1 60.1 ND LOD 113.7 81.3 ND 
D4-15-F2t-IsoP 36.1 53.4 51.2 56.9 64.5 30.2 56.6 56.9 76.1 80.0 81.9 100.8 
R% D4-15-F2t-
IsoP 
28.6 42.4 40.7 45.2 55.9 26.2 49.1 49.4 59.7 62.7 64.3 79.0 
RC 15-F2t-IsoP ND 115.67 130.11 ND ND 103.7 122.2 ND LOD 181.3 126.5 ND 
Cart = Extraction cartridge 
